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Background: Metformin is an emerging option for treating gestational diabetes 
(GDM). The evidence for the comparative safety and effectiveness of metformin versus 
insulin (standard of care) is inconclusive.  
Objective: To measure the comparative safety and effectiveness of metformin versus 
insulin for pharmacological management of GDM. 
Methods: We conducted a cohort study using New Zealand healthcare data (2005-
2015). We identified pregnant women treated with metformin or insulin for GDM and 
excluded women with evidence of preexisting diabetes.  We assessed birth outcomes using 
maternity care and hospitalization data. We examined child growth and psychosocial 
development as measured by parent- and teacher-reported Strengths and Difficulties 
Questionnaires (SDQ), recorded during pre-school health assessments at age 4. We 
adjusted for measured covariates using inverse probability of treatment weights and used 
multiple imputation for missing covariates. For dichotomous outcomes, we estimated risk 
differences (RD) per 100 and risk ratios (RR) with 95% confidence intervals (CI) and used 
linear regression for continuous measures.  
Results: We identified 7,268 pregnancies treated initially with metformin (n=3,818) or 
insulin (n=3,450). Treatment initiation varied by ethnicity, socioeconomic status, region and 
calendar year, though both groups were similar with respect to age, body mass index, and 
timing of diagnosis and treatment initiation. After adjustment, metformin was associated with 
iv 
a reduced risk of large-for-gestational-age (RD= -3.7, 95% CI -5.5, -1.8), and neonatal 
hypoglycemia (RD= -5.0, 95% CI -6.9, -3.2), compared to insulin. After adjustment, children 
of metformin-treated mothers were not more likely to be ≥85th percentile for weight 
(RR=1.04, 95% CI 0.93 1.16) or weight-for-height (RR=0.92, 95% CI 0.83, 1.02) than 
children of insulin-treated mothers. Children of metformin-treated mothers were not at 
significantly increased risk of having a concerning parent-reported SDQ score (RR=1.13, 
95% CI 0.88, 1.46) compared to insulin, although the upper confidence limit does not 
exclude a modest increase in risk.  
Conclusions: Metformin appears to be an effective treatment for women with GDM 
and may reduce the risk of some adverse neonatal outcomes when compared to insulin. 
Growth assessments of children of metformin-treated mothers were similar to those of 
children of insulin-treated mothers. These results will help inform future GDM treatment 
guidelines.
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CHAPTER 1 – REVIEW OF THE LITERATURE 
1.1 Background and Significance 
Over the course of a normal human pregnancy, a series of metabolic changes occur 
that promote adipose tissue growth in early gestation, accompanied by insulin resistance 
later on. In early pregnancy, insulin sensitivity is relatively unchanged or slightly increased, 
and decreases over time into mid and late pregnancy. As this occurs, insulin secretion from 
the pancreas increases to compensate (1). Insulin is produced by the body to help deliver 
glucose to the cells, and production increases during pregnancy to help transport glucose 
from the bloodstream to the developing fetus. During the second and third trimesters of 
pregnancy, placental hormone production may inhibit the action of insulin. When a woman’s 
body is unable to produce enough insulin during this time, glucose is not adequately 
diverted from the bloodstream and causes her blood glucose levels to increase more than 
normal (2-4).When this rise in blood glucose levels occurs for the first time during 
pregnancy, this condition is defined as gestational diabetes mellitus and is distinct from 
diabetes mellitus (type 2 diabetes).  
Worldwide, the incidence of GDM is increasing (2). Estimated prevalence in the 
United States has varied between 1 and 14 percent, depending on the diagnostic criteria 
being used (5). The change in prevalence of GDM from 1989-1990 to 2003-2004 in the 
United States was estimated to be a 122% increase overall (1.9% to 4.2%) (6). A recent 
examination comparing the Pregnancy Risk Assessment Monitoring System (PRAMS) 
questionnaire to birth certificate records from 2007 to 2010 revealed that the GDM 
prevalence may vary between 4.6% and 9.2%, though the 21 states and cities represented 
in PRAMS may not be representative of the entire United States. In particular, states from 
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the Southeast, where obesity prevalence and chronic disease burden tends to be higher, 
were not well-represented in this study (5). In England and Wales, the average prevalence 
of any diabetes in pregnancy is 3.5%, varying across region and ethnicity, with 
approximately 87.5% of cases attributed to GDM (7). In Australia, GDM incidence in 
recorded hospitalizations increased by 21% from 2000-01 to 2009-10 (3.6% to 4.4%) (8). 
Prevalence of GDM also increased in New Zealand by approximately 14% between 2001 
and 2012, and current prevalence varies widely by ethnicity: from 3% for New Zealand 
Europeans to 5-10% for Māori persons (9, 10). Higher prevalences can be found in India, 
where estimates approach 16.5% in a given study (11). The International Diabetes 
Foundation estimates that 16.9% of all pregnancies in women aged 20 to 49 years 
worldwide are affected by hyperglycemia, including GDM or diabetes prior to pregnancy (2). 
In Southeast Asia, the estimated hyperglycemia prevalence in 2015 was 24.2%, and an 
estimated 88% of hyperglycemia cases in pregnancy are found in low and middle income 
countries (2). Less than 10% of these cases are due to preexisting diabetes (2), thus GDM 
impacts a large number of pregnancies worldwide.   
1.2 Treatment for Gestational Diabetes 
While treatment for GDM greatly improves pregnancy outcomes (12-14), the 
question of which treatment option is best for mother and child in terms of both health status 
and ease of utilization remains unanswered. After diagnosis, patients typically receive diet 
and exercise counseling to control their condition; however, some women with GDM require 
treatment beyond lifestyle modification. The standard of pharmacologic treatment for GDM 
has been injectable insulin; however, practice has shifted towards exploring the use of oral 
hypoglycemic agents (OHAs) for this purpose. Insulin therapy requires subcutaneous 
injections, careful self-monitoring of blood glucose levels, and proper storage (15, 16). This 
increases difficulty in adhering to a treatment regimen, increasing the risk of adverse 
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outcomes stemming from substandard treatment (17). Provision of OHAs, which require less 
monitoring and do not require injections, has emerged as an alternative treatment regimen.  
One of the most important considerations for prescribing to pregnant women is 
whether or not a given medication has the potential to cross the placenta from mother to the 
fetus. Insulin has been shown to minimally cross the placenta (16), which indicates that 
there will be minimal risk to the health and development of the fetus. Certain formulations of 
insulin, such as insulin aspart, do not appear to cross the placenta at all (18). In general, 
placental transport of insulin is likely obstructed by its large molecular weight. Metformin is a 
biguianide, which acts as an insulin sensitizer mainly by reducing hepatic glucose 
production through suppression of gluconeogenesis and increasing peripheral glucose 
uptake. Metformin does not enhance insulin secretion, reducing the risk of hypoglycemia 
associated with treatment. Because of its small molecular size and low protein binding, 
metformin does cross the placenta, though the extent varies (18, 19).  A study of women 
using metformin for polycystic ovary syndrome (PCOS) demonstrated that fetal metformin 
concentrations are comparable to maternal levels (20). First trimester exposure to metformin 
for PCOS has not been associated with an increased in observed birth defects or early 
pregnancy loss (21), however, prior research may be limited by small sample sizes.  
Despite the potential for placental transport, metformin may have some advantages 
over glyburide when deciding on an OHA treatment. Metformin has been associated with 
less maternal weight gain than glyburide or insulin, which has important consequences for 
the pregnancy, delivery, and infant health (22, 23). Additionally, two RCTs which directly 
compared metformin to glyburide have observed fewer cases of macrosomia and large for 
gestational age in neonates exposed to metformin in utero versus glyburide; however, 
failure rates of metformin were also higher in these studies (24, 25). Failure rates in a recent 
trial of south Indian women were similar among women assigned metformin or glyburide, 
however, glyburide dosage differed from the trials by Moore et al and Silva et al (maximum 
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dose of 15 mg/day versus 20 mg/day) (26). Because of the ongoing concerns about 
placental transport of metformin and lack of information on long-term outcomes in children, 
there may be some hesitation to recommend metformin for first line GDM treatment over 
glyburide.   
1.3 Long-term Effects of Oral Hypoglycemic Agent Use During Pregnancy  
 In addition to the concern surrounding placental transport of metformin, there may 
also be long-term implications of how well GDM is controlled during pregnancy that 
contribute to child health as well. While GDM alone has been associated with adverse child 
outcomes, particularly childhood obesity, these associations are inconsistent and often 
attenuated after controlling for maternal body mass index (BMI) (27-29). No association 
between maternal hyperglycemia and offspring obesity at 2-3 and 5-7 years has been 
demonstrated in a subset of women participated in the Hyperglycemia and Adverse 
Pregnancy Outcomes study (30, 31). However, a study of 263 mother-child pairs found a 
positive association between increasing maternal glucose concentration and childhood BMI 
at age 3, independent of maternal prepregnancy BMI (32). Nonetheless, long-term 
metabolic outcomes related to medication management of GDM remain a high priority 
concern (33). 
Based in part on the results of the two-year follow-up to the MiG trial, there is 
speculation that metformin may have beneficial effects on the development of fat mass for 
children exposed in utero, due to a reduction in insulin resistance (34). Treatment with 
metformin for GDM has been associated with less weight gain during pregnancy than 
treatment with insulin, and metformin has been shown to contribute to weight loss in women 
of reproductive age (35). Whether or not these effects contribute to childhood obesity after in 
utero exposure is unknown. The comparative effectiveness of pharmacologic treatment 
options for GDM may therefore have implications for childhood growth, but there have been 
few opportunities to explore this in existing small, short randomized trials. 
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Additionally, both maternal prepregnancy BMI and GDM have been associated with 
adverse developmental outcomes. In a study of 1,311 mother-child pairs in the U.S., 
children of obese mothers had increased odds of problems with emotion, conduct, and 
hyperactivity (36). While the authors state that they observed differences in effects by GDM 
status, they do not present stratified results because the interaction term was not statistically 
significant.  Both pre-pregnancy diabetes and GDM were consistently associated with lower 
IQ scores in offspring at age 8 in the Avon Longitudinal Study of Parents and Children (37), 
however, small numbers of diabetes cases (n=59) contributed to wide confidence intervals 
of estimates. There is also conflicting information about how neonatal hypoglycemia, a 
common outcome of GDM, influences long-term neurodevelopment (38-40). Further 
research is needed to understand if pharmacologic treatment type for GDM influences child 
development, independent of maternal prepregnancy BMI.      
1.4 Evidence Summary for Comparative Effectiveness of Gestational Diabetes Treatments 
To date, there have been a number of randomized controlled trials comparing 
maternal and neonatal outcomes of metformin to insulin (Appendix 1). The most influential 
trial is the Metformin in Gestational Diabetes (MiG) trial, performed in 10 New Zealand and 
Australian urban obstetric hospitals (41).  Researchers enrolled 751 women aged 18 to 45 
years and diagnosed with GDM between 20 to 33 weeks of gestation. Women were 
excluded if they had a prepregnancy diagnosis of diabetes, contraindication to metformin, a 
known fetal anomaly, gestational hypertension, preeclampsia, fetal growth restriction, or 
ruptured membranes. Participating women were block randomized (block size 4) and 
stratified according to study site and gestational age at time of randomization to receive 
either a starting dose of 500mg of metformin once or twice daily with food, or insulin 
according to usual practice of the study site. A total of 731 women remained in the study for 
analysis (metformin N=363, insulin N=370). There were no significant differences between 
women assigned treatment with metformin or insulin for infant respiratory distress, 
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phototherapy, birth trauma, 5-minute Apgar score, or neonatal intensive care unit admission. 
Risk of neonatal hypoglycemia (defined as any blood glucose level <28.8 mg/dL) was 
reduced for women assigned to metformin (RR=0.41, 95% CI 0.21, 0.78), while risk of 
spontaneous preterm birth was higher among women assigned to metformin (RR=1.77, 95% 
CI 0.95, 3.28). Average gestational age at birth was slightly reduced for the metformin group 
as well (38.3 [SD=1.4] weeks versus 38.5 [SD=1.3] weeks, p=0.02). Women assigned to 
metformin experienced less weight gain from enrollment to the 37th week of gestation and 
more weight loss from enrollment to the postpartum visit, while weight gain from early 
pregnancy to enrollment was the same for both study groups, prior to randomization (41).  
Women who required supplemental insulin (N=168) were also compared to women who 
remained on metformin alone (N=195). Those requiring supplemental insulin were more 
likely to have a higher BMI, Polynesian (Pacific Peoples or Māori), and a previous GDM 
diagnosis. No differences were observed between the two groups with respect to other 
neonatal outcomes (41).  
Following publication of the primary results of the MiG trial, additional results from 
this trial have been made available. The percent increase of maternal plasma triglycerides 
from randomization to 36 weeks of gestation was greater for women assigned to metformin 
(21.9%) versus insulin (9.7%), but there were no differences observed in cord plasma 
triglycerides, neonatal metabolic markers, or anthropometric measurements (42). A follow-
up study of offspring born to women enrolled in the MiG trial (N=323) found that children 
who had been exposed to metformin in utero did not differ from children exposed to insulin 
with regard to weight, height, or abdominal fat at two years of age. However, children 
exposed to metformin had increased upper-arm circumference, subscapular skinfold 
thickness, and biceps skinfold thickness (43). These differences suggest that treatment with 
metformin may be associated with the development of less visceral fat in offspring as 
compared with insulin, though longer follow-up is needed to determine the true implications 
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of these observations. No differences in systolic or diastolic blood pressure were observed 
between children born to mothers in either treatment group (44). A separate follow-up of 
children born to MiG trial participants at age 2 found no meaningful differences in Bayley 
Scales of Infant Development Scores by treatment status, though they did observe 
differences by country (New Zealand versus Australia) (45). 
Additional evidence from smaller randomized controlled trials generally echoes the 
conclusions of the MiG trial, that metformin is safe and effective for GDM treatment. Ijäs et 
al. conducted a randomized controlled trial among 97 eligible women with GDM identified in 
primary care in Finland using risk factor-based screening (46). Forty-seven of the 
participating women were randomized to receive metformin (750mg once daily for week one, 
twice daily for week two, and thrice daily for week three), and 50 received insulin according 
to hospital guidelines. Mean birthweight of neonates did not differ significantly between the 
two treatment groups (metformin: 3712g ± 432, insulin: 3558g ± 593), while mode of delivery 
outcomes did differ by treatment: women receiving metformin were less likely to undergo 
spontaneous vaginal delivery and more likely to need a caesarean section. There were 
more cases of neonatal hypoglycemia in the insulin group (n=7 [14.0%] versus n=4 [8.5%]) 
but this outcome was rare overall. In comparing women assigned to metformin who required 
supplemental insulin versus those who did not, the mean birthweight was higher among 
women requiring supplemental insulin, but baseline BMI was also significantly higher, and 
estimated relative effect measures appear to be crude rather than adjusted for this likely 
confounder (46). A follow-up study of 18-month-old offspring born to these women revealed 
slight differences in weight for those exposed to metformin in utero (mean=12.051kg, 
SD=1.87) versus insulin (mean=11.318kg, SD=1.45). No differences were observed in 
social, emotional, or language development, which has been observed to be impacted in 
offspring born to women with GDM (47). 
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Other randomized controlled trials have concluded that metformin is similar to insulin, 
though these have largely been limited by small sample sizes (N=200 or less), limited follow-
up time, or methodological limitations (see Appendix, Table 1, page 38) (22, 48-51). Meta-
analyses of these trials have similarly stated that metformin and insulin appear to be equally 
efficacious, and in some cases, may be a better treatment option than insulin based on 
existing evidence (52, 53). However, there are still limited data on the long-term outcomes 
stemming from treatment decisions. Additionally, many of the maternal and neonatal 
outcomes studied are rare, with some studies observing fewer than 10 cases of adverse 
neonatal outcomes in each study arm.  The lack of observed differences between 
metformin- and insulin-treated pregnancies may reflect a lack of adequate power to detect 
rare outcomes and as a result, poor precision. Outcome definitions, including neonatal 
hypoglycemia, also varied among RCTs. 
There are few existing observational studies comparing the effectiveness of 
metformin and insulin for GDM treatment. The largest observational study to date was 
performed in Auckland, NZ and enrolled 1,269 women with GDM (54). Three hundred and 
seventy-one women received dietary counseling, 399 received insulin, and 465 received 
metformin (249 metformin alone, 216 metformin and insulin). Although this population was 
similar to that of the MiG trial, overall preterm birth was observed less frequently in women 
receiving metformin (12.5%) versus insulin (19.2%), though incidence of spontaneous 
preterm birth did not differ by treatment. In contrast, overall preterm birth was more common 
among metformin-treated women (12.1%) than insulin-treated women (7.6%) in the MiG 
trial, which was driven largely by spontaneous preterm birth. NICU admissions, 
hypoglycemia (defined as glucose <2.3 mmol/l), and large for gestational age were all more 
frequently observed among the women receiving insulin versus metformin or dietary 
counseling. In a comparison of women receiving metformin alone versus metformin and 
insulin, infants exposed to supplemental insulin were more likely to be large for gestational 
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age, admitted to the NICU, and experience respiratory distress, while differences in neonatal 
hypoglycemia were not significant. This study did not estimate relative effects or absolute 
differences, and observed outcomes were possibly driven by differences in baseline severity 
(54). 
Tertti et al. performed a case control study among women treated with metformin, 
insulin, or neither, matched on pre-pregnancy BMI and age in Finland (55). Many of their 
estimated effect measures are not reported because they were not statistically significant. 
Neonates with hypoglycemia were less likely to have been exposed to metformin than 
insulin in utero (crude odds ratio [OR]=0.4, 95% CI 0.2, 0.9). However, women who received 
insulin treatment had higher blood glucose levels at the time of screening, which does not 
appear to be controlled for in their analysis. In another case-control study of 200 women 
treated for GDM in the United Kingdom, half had been treated with metformin and half with 
insulin (56). Among the 127 women originally identified as being treated with metformin, 13 
required supplemental insulin, 5 stopped taking metformin because of side effects, and 9 
stopped treatment because they were uncomfortable with using a drug not licensed for use 
in pregnancy at the time (2007 through 2008). Women treated with metformin and insulin 
were similar with regard to baseline characteristics such as age, ethnicity, BMI, and 
gestational age at entry; however, insulin-treated women had higher median glucose values 
and were more likely to have had a previous diagnosis of GDM. Women who had received 
insulin experienced greater weight gain and more preterm births (n=10 for insulin, n=0 for 
metformin). Adverse neonatal outcomes were rare, however, jaundice, hypoglycemia, 
special care baby unit admissions, and birthweight ≥ 4kg were all more common in neonates 
born to women treated with insulin versus metformin (56).  
Existing observational studies of the comparative effectiveness of glyburide and 
insulin have utilized health care data in the United States, generating large sample sizes but 
suffering from certain limitations (57, 58). While point estimates from these studies largely 
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fell within the confidence intervals of estimates from previous research with respect to 
neonatal macrosomia, hypoglycemia, NICU admission, and jaundice, these estimates 
tended to be much more precise due to a large sample size. For example, the point estimate 
and 95% confidence interval for the risk ratio estimating the incidence of macrosomia in 
women treated with glyburide versus insulin were both above the null in Camelo Castillo et 
al. and Cheng et al. However, in Langer et al. and other studies (59, 60), confidence 
intervals crossed the null while point estimates remained above the null, indicating 
increased risk of macrosomia associated with glyburide, but not statistical significance. This 
degree of precision is a key benefit to large observational studies; nonetheless, Camelo 
Castillo et al. also had a large proportion of missing data on laboratory values and may have 
had residual confounding by obesity due to the use of ICD-9-CM diagnosis codes rather 
than actual anthropometric measurements. The lack of information on glucose values and 
degree of glycemic control has been cited as a major limitation of these studies and 
highlights the typical epidemiological trade-off of sample size versus granularity of data (61).  
To date, there are no studies of equivalent or better quality evaluating the comparative 
effectiveness of metformin. 
1.5 International Treatment Guidelines for Gestational Diabetes 
Despite the limitations in prior research, including small sample sizes and limited 
follow-up time, clinical guidelines for the treatment of GDM worldwide have begun to 
recommend consideration of metformin or glyburide for first-line treatment. In the US, the 
American College of Obstetricians and Gynecologists (ACOG) previously stated that insulin 
and oral medications (either glyburide or metformin) are equally efficacious and either can 
be used as first-line therapy, though insulin is currently the only treatment approved by the 
US Food and Drug Administration for treatment of GDM (62). However, in recent guidelines, 
the ACOG stance has changed based on evidence from recent meta-analyses, and now 
does not recommend either OHA as a first-line treatment (63). The choice of OHA may 
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depend on the health care system where the woman receives treatment; for example, the 
University of North Carolina Chapel Hill School of Medicine directs obstetricians to manage 
GDM patients with glyburide first (64), whereas GroupHealth Cooperative guidelines 
recommend metformin before glyburide in women who are unwilling to take insulin (65). The 
Canadian Diabetes Association notes that women who are nonadherent to or refuse insulin 
can be offered glyburide or metformin, but that use of oral agents in pregnancy is 
considered off-label and this decision should be discussed with the patient (66). In the 
United Kingdom, the National Institute for Health Care and Excellence recommends offering 
metformin first, followed by the addition of insulin if blood glucose targets are not met, or 
replacement with glyburide if metformin is not tolerated (7). Neither metformin nor glyburide 
have been approved for use during pregnancy in Australia at this time and are not explicitly 
recommended by the Royal Australian College of General Practitioners (7). There are no 
existing statements from the Royal Australian and New Zealand College of Obstetricians 
and Gynaecologists on pharmacologic treatment options for GDM. Preliminary data suggest 
that treatment with metformin has been more prevalent than treatment with glyburide in NZ. 
While treatment with metformin is endorsed by the NZ Ministry of Health (10), the NZ 
Medicines and Medical Devices Safety Authority states that the safety of metformin use 
during pregnancy is not yet established (67). While these guidelines recognize the benefits 
of providing OHA medications to women with GDM, they note that more information on the 
long-term consequences of this treatment decision is needed. 
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CHAPTER 2 – SPECIFIC AIMS 
2.1 Specific Aims 
GDM is a frequently observed pregnancy complication characterized by glucose 
intolerance, and incidence is expected to increase with rises in maternal obesity (2, 68). 
Women with elevated blood glucose are at increased risk for delivery of large-for-gestational 
age infants, and there is a strong monotonic association between maternal glucose control 
and infant birthweight (69, 70). Up to one-third of women with GDM require pharmacologic 
treatment to achieve adequate glucose control (15, 71). While glucose control greatly 
improves pregnancy outcomes (12, 14, 72), the question of whether OHAs are as safe and 
effective as injectable insulin for the mother and her infant remains unanswered. Injectable 
insulin has previously been the standard of care for GDM; however, glyburide and metformin 
(both OHAs) have become increasingly used for this indication (15). Recently, the safety 
and effectiveness of OHAs has been identified as a priority research topic (33). Limited 
randomized controlled trials and observational studies have compared the treatments with 
regard to immediate maternal and infant outcomes; however, the effectiveness of OHAs for 
this purpose has not been definitively established. While prior research comparing 
metformin to insulin has concluded that metformin is safe for use during pregnancy (22, 41, 
46, 48-52, 55), these studies had limited analytic power to examine less frequent outcomes 
or heterogeneity of treatment effects, and short follow-up times prevented evaluation of 
long-term effects. While U.S. providers have primarily turned to glyburide as the OHA of 
choice for GDM, but emerging research from large observational studies (n≈9,000) 
suggested that glyburide may be associated with more adverse neonatal outcomes than 
insulin (57). The studies of metformin have not been adequately powered to evaluate 
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differences in these outcomes, despite international recommendations to prescribe 
metformin as an alternative to insulin for GDM (7, 10, 66).   
Therefore, we propose to examine the comparative effectiveness of metformin 
versus insulin for the treatment of GDM in a longitudinal observational study using routinely 
collected health care data from New Zealand (2005 to 2015). These extant data sources are 
readily linked, and will provide data on pharmaceutical dispensing, primary maternity care 
services, laboratory data, and postpartum outcomes for mothers and their infants for 
pregnancies requiring pharmacotherapy for GDM. We will also examine child growth and 
development outcomes assessed at age 4 from a pre-school screening program introduced 
in 2009. Linking these data sources will allow us to report precise measures of any 
differences between the treatment groups with robust control of key confounders (glucose 
control and pre-pregnancy obesity). 
2.1.1 Specific Aim 1 
Aim: Measure the comparative effectiveness of treating GDM with metformin versus 
insulin on perinatal and neonatal outcomes in pregnant women and newborns. To 
accomplish this, we will estimate risk ratios, risk differences and 95% confidence intervals to 
compare the incidence of adverse maternal outcomes (e.g., preeclampsia, caesarean 
section delivery, induction) and adverse neonatal outcomes (e.g., preterm birth, large for 
gestational age, macrosomia, and neonatal hypoglycemia) in pregnancies treated with 
metformin versus those treated with insulin. 
2.1.2 Specific Aim 2 
Aim: Estimate the association of treating GDM with metformin versus insulin with 
adverse child health outcomes. Using data obtained from the B4 School Check health and 
development visit offered at age 4 in children born between 2005 and 2012, we will obtain 
measures of height, weight, and the results of a screening questionnaire to assess 
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psychosocial development of children born to mothers treated with metformin or insulin for 
GDM. 
2.2 Hypotheses 
Based on results from published randomized controlled trials and meta-analyses, we 
hypothesize that metformin will be a non-inferior treatment option to insulin with respect to 
infant birthweight, an indicator of how well treatment is able to control a mother’s 
hyperglycemia. We expect the treatment groups to be similar but differ based on markers of 
disease severity like maternal BMI and timing of treatment initiation. We hypothesize that 
metformin will be associated with a reduced risk of certain neonatal events, based on meta-
analysis results. We further expect to observe no meaningful differences in child growth or 
psychosocial development when comparing children born to mothers treated with metformin 
versus insulin for GDM. 
2.3 Rationale 
To date, there are no large studies comparing the effectiveness of metformin versus 
insulin. Although randomized controlled trials have long been considered the gold standard 
of clinical research, observational studies have many advantages for determination of real-
world comparative effectives of two therapies. Observational research is comparatively 
affordable and practical, as treatments are not provided and assigned by the study, but 
rather are observed in regular clinical practice, allowing for consideration of real-life 
treatment determinants. Additionally, the use of secondary data that is routinely collected 
leads to greater efficiency in research. The availability of longitudinal health care data allows 
us to examine long-term outcomes of treatment decisions without waiting years for these 
outcomes to materialize. Furthermore, observational research using extant data is less 
subject to volunteer bias and loss to follow-up, which are often major threats to validity in 
prospective studies. These advantages are particularly relevant to the comparative 
effectiveness of metformin versus insulin, as the prevailing concern about metformin 
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treatment for GDM is the extent to which it impacts the long-term health of the offspring due 
to placental transport. Although the MiG trial, the largest trial to date, has planned to 
examine outcomes in children born to women participating in the study at age 5, there has 
already been significant loss to follow-up (44%) observed at the 2-year follow-up (43). A new 
prospective experimental study would need an even larger initial sample size, which quickly 
becomes prohibitively expensive and difficult to recruit.   
As the prevalence of GDM increases and more women require pharmacologic 
therapy to achieve glucose control, it is important to study the comparative benefits and 
risks of different treatment options. Optimization of medical management of GDM could 
greatly improve pregnancy outcomes for a growing population of women. By using existing 
health care data, we are able to follow a large population of mothers and their children 
longer than in most randomized controlled trials with more comprehensive follow-up. When 
completed, this study will represent the largest study to date to compare metformin to insulin 
for GDM treatment. Our findings have the potential to inform clinical practice and provide 
needed data on the long-term effects of in utero exposure to metformin.
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CHAPTER 3 – METHODS 
3.1 Data Sources 
We conducted a retrospective observational cohort study of pregnant women who 
delivered between 2005 and 2015, and their offspring. This study was conducted in the NZ 
population, due to the availability of extant secondary health care data and knowledge that 
metformin has been recommended to treat GDM in clinical practice. The NZ Ministry of 
Health maintains 20 District Health Boards for the purpose of funding, planning, and 
providing health services. From this, approximately 14 individual collections of health 
information exist, initially collected for payment, funding, or monitoring, though recently there 
has been more focus on research. Because health services in NZ are funded by the 
government, eligible persons may receive free inpatient and outpatient public hospital 
services, including pregnancy services, and subsidies on prescription items (73). Data 
collections are linkable through an encrypted National Health Identifier (NHI). This also 
includes linkages between mother and child through unique identifiers, allowing us to 
directly examine infant and child outcomes of medications used during pregnancy. Utilizing 
previously collected data allowed us to conduct analyses at relatively low-cost while being 
confident that these data are of high quality and valid.  
These longitudinal health data are a rich source of information on prescription 
dispensing, maternal health status, and infant and child health outcomes. The linked data 
resources in NZ data for an entire population, rather than restricting to insured individuals, a 
single clinical center, or study volunteers. Additionally, existing NHI number linkages 
between mother and child simplified long-term follow-up and improved rates of loss-to-
follow-up and missing data.  
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Multiple data collections were linked with mother and child NHI numbers, including 
the National Health Index (NHI), Database, National Maternity Collection (MAT), 
Pharmaceutical Claims Data Mart (PHARMS), National Minimum Data Set (NMDS), 
Mortality Dataset (MORT), Laboratory Claims Collection, and B4 School Checks (B4SC) 
(73, 74). Brief descriptions of each collection are available in Table 1. Mother-infant pairs 
were previously linked and available in MAT via unique pregnancy identifiers that link to 
National Health Identifiers (NHIs) for mothers and infants. All data were requested with 
encrypted NHI numbers to protect the identity of individuals in the study. Linkage between 
data sources was accomplished using the encrypted identifiers.  
3.2 Study Population 
New Zealand is a Pacific Island nation with a population of approximately 4.5 million 
people. The majority ethnicity is NZ European (68%), followed by the indigenous Māori 
population (15%), Asian (9%). and Pacific Peoples (7%) (74). The proportion of pregnancies 
experiencing GDM has increased in NZ, with an annual increase of nearly 14% between 
2001 and 2012 (76). Prevalence of GDM varies widely by ethnicity, reported as 3% for New 
Zealand Europeans to 5-10% among Māori, 4-8% percent among Pacific peoples, and 4-8% 
among Asian Indians (10). It is likely that the rates of GDM among Māori and Pacific women 
reflect disparities in screening during the time these data were collected and are in fact, 
higher than currently measured. 
Pregnancies were identified using the MAT which provides information on primary 
maternity services from the first midwife encounter through the postpartum period for 
pregnancies with a duration or 20 weeks or later, or resulting in an infant weighing at least 
400 grams at delivery. This includes information from midwife encounters and 
hospitalizations. Because stillbirths are not reliably reported in MAT, we linked available 
mortality data from years 2005 to 2013 to more accurately classify infant birth outcomes. We 
estimated the start of pregnancy using gestational age as reported in MAT. Gestational age 
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in MAT is reported as either the duration of completed weeks between a woman’s self-
reported last menstrual period (LMP) date and her delivery date or derived from a clinical 
assessment during pregnancy or at birth. For those missing gestational age but having a 
recorded date of LMP, we estimated gestational age by calculating the number of completed 
weeks from the LMP to the delivery date. If both LMP and gestational age were missing, we 
removed these deliveries from our cohort.  
Pharmaceutical data from the PHARMS are reliably available from 2005 onwards. 
Thus, in order to ensure that we observed the full 6-month lookback history of prescription 
use for each pregnancy, we restricted our cohort to pregnancies with an estimated start date 
of June 30, 2005 or later. We additionally excluded pregnancies if the mother was younger 
than 15 years old at delivery, or older than 45 years old. Finally, we excluded pregnancies 
with missing information on gestational age.   
3.3 Exposure Assessment 
We limited our cohort to pregnancies complicated by GDM. In NZ, according to 
national guidelines, women are first screened for gestational diabetes with the “post-
polycose” glucose tolerance test (10). If the value of this test is ≥7.8 mmol/L they will 
undergo the oral glucose tolerance test and diagnosed with GDM if the fasting test result is 
≥5.5mmol/L or the 2-hour test result is ≥9.0mmol/L. Following diagnosis of GDM, New 
Zealand women are provided with a blood glucose meter for home-based glucose testing 
and are given a prescription for testing strips (personal communication, Lesley MacLennan, 
Counties Manukau District Health Board). Because these prescriptions are subsidized by 
the NZ government, claims are filed for payment to the NZ Pharmaceutical Management 
Agency (PHARMAC) and recorded in the PHARMS collection. We considered a claim for 
prescription blood glucose test strips to be evidence of a GDM diagnosis in each pregnancy 
if the first prescription was filled after the start of the GDM screening period, 24 weeks 
gestation. If a prescription for test strips was filled anytime during the lookback period (6 
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months prior to pregnancy through 24 weeks gestation), we considered this to be evidence 
of prior type 2 diabetes and excluded these pregnancies. We used a shorter lookback period 
(3 months prior to pregnancy) for women with closely spaced pregnancies. This was done to 
avoid excluding pregnancies immediately following a pregnancy complicated by GDM and 
beginning less than 6 months after the prior delivery. We also examined claims for 
antidiabetic medications (insulin, metformin, glibenclamide, glipizide, glicazide, pioglitazone, 
and acarbose) and excluded women who had a prescription claim for any antidiabetic prior 
to 24 weeks gestation. 
The cohort was further restricted to women who were treated pharmacologically with 
metformin, insulin, or both. For women who received both metformin and insulin during their 
pregnancy for the first time after filling a test strip prescription, we defined “combination 
therapy” as a dispensing for both medications within 7 days of the first claim. We treated 
combination therapy co-initiators as a separate group, as the need for both medications may 
have indicated an additional degree of GDM severity. For our primary analyses, we 
restricted our study population to pregnancies initially treated with metformin or insulin 
monotherapy. A woman who later added another therapy (>7 days after the first claim) 
remained in the cohort and analyzed as part of the treatment group with which she started. 
Exposure classification was based on first prescription dispensed for primary analyses, 
using a first-treatment-carried-forward approach for effectiveness. 
3.4 Outcome Assessments 
3.4.1 Outcome assessment for Aim 1 
A summary of all targeted outcomes is presented in Table 3.2. In Specific Aim 1, we 
will assess the comparative effectiveness of treating GDM with metformin versus insulin on 
perinatal outcomes in pregnant women and newborns (Figure 3.1). Perinatal outcomes will 
primarily be obtained from the MAT collection, with enhancement from NMDS where 
information is not available in MAT.  
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3.4.1.1 Maternal outcomes 
The risk of the following maternal outcomes will be compared between women 
initiating metformin treatment versus insulin: 
Caesarean section delivery 
Caesarean births, or c-sections, are defined as surgical deliveries of an infant 
through incisions made in the mother’s abdomen and uterus. There are a number of risk 
factors for a c-section, including problems with the placenta, failure of labor to progress, 
multiple gestation pregnancy, a large fetus, or maternal medication conditions such as 
diabetes or high blood pressure (75). C-section delivery was measured using variables from 
the MAT collection, which distinguish between elective caesarean deliveries (performed as a 
planned procedure before or after the onset of labor, when the decision was made prior to 
commencement of labor) versus emergency caesarean (indicating that it was performed as 
an emergency procedure before or after the onset of labor). Both elective and emergency 
caesarean deliveries were of interest. Emergency caesarean deliveries may occur during 
birth because of problems with labor. Elective caesareans may be indicated, however, for 
women with anticipated problems, including a large-for-gestational age neonate. In NZ, c-
section deliveries are commonly performed surgical obstetric interventions, with 
approximately one-quarter (24.3%) of women giving birth via caesarean section over the 
past decade (23.0-25.3%). Among these, approximately half were emergency caesarean 
section deliveries and others were elective. From 2004 to 2013, elective caesarean section 
deliveries increased from 8.8% of live births to 12.0% (76). Because both outcomes are 
plausible downstream consequences of GDM, we considered both types of c-section 
deliveries in our analysis. In MAT, these variables indicating the procedure was performed 
were derived from ICD-10-AM delivery procedure codes available in the NMDS.  
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Induction of labor 
Labor induction refers to the use of medications or other methods to cause 
contractions to start and induce labor. This is generally limited to situations where there is a 
problem with the pregnancy, or when the baby is overdue (77). This was defined using 
dichotomous variable indicting whether or not a woman received a medical or surgical 
induction of labor during a delivery event, available from MAT and based on ICD-10-AM 
obstetric procedure codes. 
Severe perineal trauma 
Severe perineal trauma is defined as third- or fourth-degree perineal tears during 
childbirth. Third-degree tears are defined as partial or complete disruption of anal sphincter 
muscles. A fourth-degree tear involves the disruption of anal sphincter muscles with a 
breach of the rectal mucosa (78). Fecal incontinence may result from perineal tears in 29 to 
57% of affected patients. High birth weight is considered a risk factor for perineal tears (79). 
Severe perineal trauma was defined by a flag third or fourth degree perineal tears or 
surgical repair of a tear taking place during a delivery event, derived from the MAT data 
collection. These variables were based on selected ICD-10-AM diagnosis codes during the 
delivery event.  
Preeclampsia  
 Preeclampsia is defined by high blood pressure (greater than 140/90) occurring after 
20 weeks or pregnancy, after experiencing normal blood pressure in the beginning of 
pregnancy. This condition is also accompanied by increased swelling and protein in the 
urine (80). While an increased risk of preeclampsia has been observed among women with 
GDM (81, 82), the exact relationship is unclear, as preeclampsia may have begun to 
develop before GDM is recognized. More severe GDM has been associated with increased 
risk of preeclampsia (83), suggesting that glucose control is an important determinant of 
preeclampsia incidence. Previous comparisons of metformin and insulin have not shown 
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significant differences in preeclampsia incidence between treatment groups, though the risk 
of preeclampsia is often lower in women treated with metformin. To examine this outcome, 
we identified diagnoses of preeclampsia in NMDS hospitalization data.  
3.4.1.2 Infant outcomes 
The incidence of the following neonatal outcomes will be compared between women 
initiating metformin treatment versus insulin: 
Macrosomia/Birthweight 
Macrosomia is defined as a birthweight of >4,000g or >4,500g or more, regardless of 
gestational age. We used 4,000g as the primary cut-off in analyses, as this is the definition 
cited in the NZ clinical guidelines for GDM screening and treatment (10). Birthweight of the 
infant at time of birth in grams was also available as a continuous measure, usually 
measured to the nearest 5g and obtained within one hour of birth. Thus, we were able to 
evaluate macrosomia as a dichotomous variable according to NZ definitions, as well as 
measure birth weight continuously. Fetal macrosomia is a common outcome of GDM and 
may lead to other adverse outcomes such as birth injuries and hypoglycemia.  
Large for gestational age 
 Large for gestational age (LGA) is defined as a birthweight greater than the 90th 
percentile for age. An infant that is LGA is larger than expected for his/her age and gender 
and is a common outcome of gestational diabetes (2, 84). Current age-, sex-, and ethnicity-
specific birthweight percentiles were not available for our study population. To obtain this 
information, we calculated these birthweight percentiles for infants born between 2001 and 
2015 in NZ using available data in the MAT data collection. We categorized infants as LGA 
if their birthweight exceeded the 90th percentile, based on their gestational age, sex, and 
ethnicity.   
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Neonatal hypoglycemia 
 Neonatal hypoglycemia (low blood sugar) occurs when the infant does not have 
enough glucose in their blood that is needed for energy. This is a major concern in 
pregnancies complicated by GDM. Because glucose is primarily needed for the infant’s 
brain, neonatal hypoglycemia may have long-term implications for neurodevelopment. 
Transient hypoglycemia, which occurs when a single initial measurement of glucose 
concentration is low, followed by a second measurement above a defined cutoff, has 
recently been linked to lower test achievement scores in childhood (38), though these 
findings have yet to be replicated. In addition, there are no uniform management guidelines 
for infants with low glucose concentrations with no overt symptoms (85, 86). Neonatal 
hypoglycemia was defined as an outcome using clinical codes (ICD-10-AM) available 
through the NMDS.  
Respiratory distress 
 In Vignoles et al., women with either pregestational diabetes or GDM were more 
likely to deliver a neonate that suffered from severe respiratory failure (87). While metformin 
has generally not been associated with respiratory distress, glyburide was associated with 
an increased risk over insulin in Camelo Castillo et al.(57). The association of metformin and 
respiratory distress may have been difficult to detect in small studies because it has been a 
rare outcome (3.8% in the MiG trial) (41). To determine neonatal respiratory distress in our 
study, we identified diagnoses from clinical codes in NMDS.  
Shoulder dystocia 
 Shoulder dystocia occurs during a vaginal delivery when, following delivery of the 
fetal head, additional obstetrics maneuvers are required to continue delivery. This can lead 
to birth injuries like brachial plexus injuries and fractures of the clavicle or humerus. 
Additionally, these complications are associated with postpartum hemorrhage and fourth-
degree tears (88). GDM is associated with an increased risk of shoulder dystocia (89). 
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Macrosomia also increases the risk of shoulder dystocia, as well as maternal obesity or 
excessive weight gain (90). A preliminary examination of NZ hospital admissions from 2006 
to 2013 for infants with relevant ICD-10 codes for conditions related to pregnancy and 
childbirth (O66.X) revealed that the incidence of shoulder dystocia is low in the general 
pregnant population (approximately 0.3%). While it’s estimated that the incidence of 
shoulder dystocia is closer to 0.6-3% (91), this estimate pertains to vaginal deliveries only; 
our denominator for the NZ hospital admissions would include c-section deliveries as well. 
We used ICD-10-AM diagnosis codes for hospital admissions recorded in the NMDS to 
identify shoulder dystocia cases.    
Preterm birth 
Preterm birth, defined as delivery prior to 37 completed weeks of gestation, is a 
pregnancy outcome with a complicated etiology. There are many known risk factors for 
preterm birth in singleton pregnancies, including GDM, sexually transmitted infections, 
maternal age, smoking, stress, being either underweight or obese before pregnancy, 
ethnicity, and certain environmental exposures (92).  The association of treatment with 
metformin for GDM and preterm birth is unclear. In the MiG trial, researchers found an 
increased risk of preterm birth overall associated with metformin versus insulin (RR=1.60, 
95% CI 1.02, 2.52) (41). However, in Goh et al., an observational study conducted in a 
similar setting, there were more preterm births observed in women who received insulin 
treatment as compared with women receiving metformin (54).  The MAT data collection 
contains information on gestational age, which is derived from either the first day of the 
woman’s last menstrual period, a clinical assessment during pregnancy, or examination of 
the infant after birth. We used a dichotomous variable for preterm birth (less than 37 weeks 




 Stillbirth is a recognized adverse outcome of pregnancies complicated by preexisting 
diabetes (93, 94); however, the relationship with GDM is less clear. Although an increased 
risk of stillbirth has not been universally observed among women with GDM, studies may 
have been too small to detect such a rare outcome, or methodologically flawed (95). 
According to a recent study by Hutcheon et al., studies of GDM and stillbirth may be 
impacted by immortal time bias by beginning follow-up at 20 weeks awhile requiring 
pregnancies to survive to 24-28 weeks in order to receive a GDM diagnosis (96). In an 
analysis restricting to births occurring after 28 completed weeks of gestation, Hutcheon et al 
observed increased odds of stillbirth associated with GDM (OR=1.25, 95% CI 1.11-1.41). 
We defined stillbirth based on NZ mortality data.  
Neonatal intensive care unit admissions 
Neonatal intensive care unit (NICU) admissions may be indicated from newborns 
suffering from conditions closely related to GDM, including macrosomia, respiratory distress, 
or hypoglycemia. In a study of pregnancies complicated by GDM or type 2 diabetes in the 
National Women’s Health database in Auckland, NZ from 1999 to 2000, 29% of NICU 
admissions were a result of GDM complications (97). The incidence of NICU admissions 
ranged from 12.7% in the metformin group to 18.7% in the insulin group in the Goh et al. 
observational study occurring in Auckland, NZ. (54) The NMDS contains detailed information 
on hospitalization events, including a Health Specialty Code to broadly categorize the event 
type (e.g. cardiology, oncology, rheumatology). Included are two codes that indicate if an 
infant’s event took place in a Level II or Level III NICU (P42 and P43). While we were able to 
use these codes to determine if an infant was admitted to the NICU, we were not able to 
accurately assess the number of hours the infant remained under special care. The amount 
of time an infant spends in the NICU may provide information about the severity of the 
condition for which they are under care. To estimate this without exact measurements on 
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length of stay, we examined the proportion of infants who were discharged from the hospital 
after their mothers were discharged. This would suggest that the infant needed care for 
longer than a standard hospitalization, and likely wouldn’t include the proportion of infants 
who are in the NICU for less severe conditions.   
3.4.2 Outcome assessment for Aim 2 
For Specific Aim 2, we assessed the comparative safety and effectiveness of treating 
GDM with metformin versus insulin on long-term childhood outcomes at age 4 (Figure 1). As 
noted above, the long-term effects of metformin treatment have not been extensively 
studied. Metformin crosses the placenta while insulin does not, causing concerns that that 
treatment with metformin may impact fetal development in ways that insulin would not and 
result in adverse childhood outcomes. To explore this, we leveraged regularly collected data 
on children in NZ at age 4 through a pre-school readiness assessment called the B4 School 
Check (B4SC). The B4SC program began in 2009 and offers a comprehensive health and 
development screen for 4-year-old children prior to school entry. From 2009 to 2012, 
participation varied from 52.5 percent to 75.6 percent in 2012; overall, participation rates 
during those 4 years was 66.3 percent. In 2015-16, participation was nearly 100% (98). We 
incorporated data from all available years (2010 through mid-2017), following infants born to 
women treated for GDM between 2006 and mid-2012.  
3.4.2.1 Child outcomes 
Growth outcomes 
As part of the B4SC assessment, providers measure a child’s height and weight. 
Providers are instructed to take all measurements on a hard surface. Weight is measured 
using a Seca 862 electronic floor scale or Tanita WB 100 S MA floor scale (or Seca 770 or 
Tanita HD-351 weighing scale). Height is measured using a Leicester Height Measure 
portable stadiometer or a Seca 214 portable stadiometer. Providers are further instructed to 
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take two readings of each measurement (height, weight, height, weight) and if the 
measurements do not vary by greater than 0.5kg for weight or 0.5cm for height, the reported 
measurement is the average of the two, rounded to the nearest 0.1kg or cm. If the 
measurements do differ by more than 0.5kg or 0.5cm, providers are instructed to take a third 
reading and average the two closest measurements (99).   
We used height and weight values from the B4SC to calculate child BMI. These 
values were also used to estimate z-scores and percentile-based outcomes for weight, 
height, weight-for-height, and BMI. We used the 2006 World Health Organization (WHO) 
reference standards to calculate sex- and age-specific z-scores and percentiles (100). We 
used the 85th percentile as a cutpoint for defining overweight and obesity in children and 
applied this cutpoint for creating dichotomous outcomes for each growth measurement. We 
also examined the proportion of children with weight, height, weight-for-height and BMI z-
scores ≥1 or ≥2. Additionally, the B4SC recommends referral for children with weight above 
the 97th percentile and BMI of 21 or over. We therefore used the 97th percentile as a 
cutpoint for extreme growth measurements and examined the proportion of children with a 
BMI measurement of 21 or over.   
Behavioral and emotional development outcomes 
The B4 School Check offers screening to help identify children that may need help 
with learning and development before entering school using the Strengths and Difficulties 
Questionnaire (SDQ) (101, 102). The SDQ is designed to assess the child’s strengths in five 
subscales pertaining to different emotions or behaviors: prosocial behavior, hyperactivity, 
emotional symptoms, conduct, and peer problems (Appendix, Table 4). In New Zealand, the 
SDQ is offered in two different formats, depending on whether a parent or a teacher is 
administering the questionnaire. Parents or teachers respond, “not true”, “somewhat true”, 
or “certainly true” to each statement pertaining to the child’s behavior (e.g., “Considerate of 
other people’s feelings”, “Often loses temper”) in addition to other questions about emotional 
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difficulties. This instrument has been previously shown to be valid and reliable (101, 102). 
Responses to these statements can be organized into the four subscales of hyperactivity, 
emotional symptoms, conduct, and peer problems. Scores from these subscales are 
summed to result in a Difficulties Score which can range from 0 to 40, with higher scores 
indicating concern and possible need for referral.(99, 101, 103) The cut-off for a 
“concerning” score is typically 17 for the parent-completed SDQ and 16 for the teacher-
completed SDQ; however, a review of the SDQ in the NZ population found that a lower cut-
off is more appropriate (14 for SDQ-P, 11 for SDQ-T).(104, 105) An additional prosocial 
behavior scale is not included in the total Difficulties Score, and is scored so that an 
absence of prosocial behavior (e.g. helping, sharing) receives a lower score. 
3.5 Covariates and Treatment Effect Heterogeneity 
We identified potential confounders of the association between GDM treatment and 
our primary effectiveness outcome, birthweight, by reviewing literature and consulting 
clinical experts. We assessed covariates in the baseline period (6 months prior to pregnancy 
through 23 completed weeks of gestation). These covariates included maternal age, BMI, 
timing of diagnosis and treatment, geographic region, ethnicity, socioeconomic status, 
parity, and smoking status. Most maternal characteristics were recorded in MAT. For 
demographic characteristics (age, ethnicity, region, socioeconomic status), we used the 
MAT data collection as our primary source and augmented missing MAT data with available 
information in the NHI. Noting that prevalence of GDM and availability of treatment may vary 
across regions of NZ, we used the territorial local authority of the mother’s residential 
address is recorded at the time of delivery in the MAT data collection in our analysis. 
Additionally, GDM prevalence varies across ethnic groups in NZ. The mother’s self-identified 
ethnic group is categorized as prioritized ethnicity, ethnicity code 2, and ethnicity code 3. We 
used prioritized ethnicities in our analyses and reported the proportion of women who 
reported a given ethnicity in any of the three categories. To measure socioeconomic status, 
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we used the NZ Deprivation Index (NZDep13). The NZDep13 combines census data related 
to income, home ownership, employment, qualifications, family structure, housing, and 
access to transportation or communications into a score for measuring relative 
socioeconomic deprivation. These scores are measured on a meshblock level, which is the 
smallest geographical area defined by Statistics New Zealand, and generally comprises 60 
to 110 individuals. These scores are grouped into deciles, with a score of 1 indicating an 
area with the least deprived scores (106, 107). 
The key health characteristics that we measured were maternal BMI, timing of 
diagnosis and treatment, smoking status, and parity. Maternal BMI was measured at the 
time of the first Lead Maternity Care (e.g., midwife, obstetrician) visit for a given pregnancy 
in the MAT data collection. This means that women may not have BMI measured until later 
in their pregnancy, if they did not seek prenatal care earlier. For our study, we used BMI 
measurements that were recorded prior to the initiation of GDM treatment and set other 
measurements to missing if they were taken after the prescription fill date. The timing of 
GDM recognition and treatment may have an impact on pregnancy outcomes and the initial 
treatment assignment (i.e., later recognition of worse glucose control may require 
management with insulin). We determined the timing of diagnosis and treatment based on 
dates of prescription claims for diagnostic test strips and antidiabetic treatments. We also 
characterized women as having a previous diagnosis of GDM if they met our diagnostic 
criteria in a previous pregnancy, and likewise characterized them as being treated for GDM 
if they met the eligibility criteria of metformin or insulin treatment for GDM more than once. 
Maternal smoking is an important risk factor for neonatal outcomes like preterm birth and 
stillbirth.  Although there is no clear link between smoking and GDM, it could be an indicator 
of other lifestyle choices that we were unable to measure, such as nutrition. We will explore 
this as a possible confounder based on reported smoking status at the first encounter with 
the Lead Maternity Carer, as stored in the MAT data collection. Parity, defined by the 
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number of pregnancies lasting until a viable gestational age, was similarly measured in the 
MAT data collection and women were categorized as having 0, 1, 2, or 3 or more prior 
pregnancies.  
Comparative effectiveness and safety of metformin versus insulin may vary by 
observable factors. We explored treatment effect heterogeneity by maternal ethnicity and 
infant sex. To achieve this, we presented stratified effect estimates of risk ratio and risk 
difference from stratified models for Aim 1 and presented stratified risk ratio estimates for 
the interaction with sex for Aim 2.   
3.6 Statistical Analysis 
For Specific Aim 1, we created a uniform period of follow-up between the initial anti-
diabetic prescription and 92 days postpartum. While duration of pregnancy after initial 
treatment varied, we maintained uniform follow-up on the time scale of initial prescription to 
end of the perinatal period. We similarly maintained a uniform follow-up period between 
initial prescription and assessment at the B4SC. For this reason, we were able to calculate 
risks in our cohort. We used log-binomial regression to estimate risk ratios and 95% 
confidence intervals and linear risk models to estimate risk differences and 95% confidence 
intervals. For continuous outcomes (i.e., birthweight, z-scores) we used linear regression to 
estimate to model the relationship between metformin treatment as compared with insulin 
treatment for GDM and these outcomes.  
Multiple imputation using chained equations was used to estimate missing covariate 
information (108). BMI was measured at the first prenatal care encounter in NZ, which 
means some women may have had their BMI recorded late in pregnancy. We reassigned 
extreme BMI values (<14 and >72) to missing. We then used multiple imputation to estimate 
BMI for pregnancies with missing data, including reassigned extreme values. We similarly 
imputed values for maternal ethnicity, smoking status (yes/no) and parity (0, 1, 2, or 3 or 
more prior births) at the time of the first LMC encounter.  
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To control for identified covariates, we estimated propensity scores for each 
pregnancy, calculated as the estimated probability of treatment with metformin based on 
measured covariates using logistic regression. We then used these values to estimate 
inverse probability of treatment weights (IPTW), calculated as the inverse of the probability 
of receiving the treatment actually received. Because women could contribute multiple 
pregnancies to our study, we used generalized estimating equations to account for within-
woman correlations. We specified an independent correlation structure in IPT-weighted 
models, as is recommended (109). We assessed balance of covariates pre- and post-
weighting by calculating standardized mean differences for individual covariates for 
comparison. 
3.7 Software and Approval 
All analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC). This study 
was approved by the NZ Health and Disability Ethics Committee (Reference 16/NTA/66) and 






3.8 Tables and Figures 
Figure 3.1 Study schematic  
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Table 3.1 Summary of New Zealand Data sources 
Data Source Description Years Available 
National Health Index 
Database (NHI) 
Contains demographic information for 
those assigned a National Health 
Identifier 
2004 - 2015 
National Maternity 
Collection (MAT) 
Contains data on primary maternity 
services and on inpatient and day-
patient health event data during 
pregnancy, birth, and the postnatal 
period for women and their babies. 




Contains information on all subsidized 
prescriptions dispensed from community 
pharmacies. 
2003 - 2015 
National Minimum Data 
Set (NMDS) 
Contains records of all hospital 
discharges in New Zealand. 
2003 - 2015 
Mortality Dataset (MORT) Classifies the underlying cause of death 
for all deaths registered in NZ, including 
all registered fetal deaths. 
2004 - 2013 
Laboratory Claims Data 
Warehouse 
Contains claim and payment information 
for community laboratory tests. 




Table 3.2 Outcome definitions 
Outcome Defined By Data Source 
Maternal Outcomes 
Elective c-section  
ICD-10-AM delivery procedure code (O82.0, 
1652000, 1652002) 
NMDS, MAT 
Emergency c-section  
ICD-10-AM delivery procedure code (O82.1, 
1652001, 1652003) 
NMDS, MAT 
Induction of labor 
ICD-10-AM obstetric procedure code 





ICD-10-AM diagnosis codes (O70.2, O70.3, 
1657300) 
NMDS, MAT 
Preeclampsia ICD-10-AM diagnosis codes (O14.X) NMDS 
Infant Outcomes 
Birthweight Birthweight in grams MAT 
Macrosomia 
(birthweight) 
Birthweight in grams (>4,000g) MAT 
Large for gestational 
age 
Birthweight in grams (> 90th percentile) MAT 
Neonatal 
hypoglycemia 
ICD-10-AM diagnosis codes (P70, P70.0, 
P70.1, P70.3, P70.4) 
NMDS 
Respiratory distress 
ICD-10-AM diagnosis codes (P22, P22.0, 
P22.1, P22.8, P22.9) 
MAT/NMDS 
Shoulder dystocia ICD-10-AM diagnosis codes (O66, O66.0) NMDS 
Preterm birth Delivery <37 completed weeks of gestation MAT 
Stillbirth Fetal death after study entry (24 weeks) Mortality Collection 
NICU admission Health Specialty codes (P42, P43)  NMDS 
Child Outcomes 
Child growth (height, 
weight, body mass 
index) 
Height and weight measurements B4 School Check 
Growth percentiles 
Height and weight measurements, compared 
with 2006 World Health Organization reference 
standard 
B4 School Check, 
WHO 
Growth z-scores 
Height and weight measurements, compared 
with 2006 World Health Organization reference 
standard 




Summed scores for emotional problems, 
conduct problems, hyperactivity/inattention, 
and peer relationship problems parent-reported 
subscales 
B4 School Check 
SDQ-Teacher 
Difficulties Score 
Summed scores for emotional problems, 
conduct problems, hyperactivity/inattention, 
and peer relationship problems teacher-
reported subscales 
B4 School Check 
Prosocial behavior 
(parent-reported) 
Subscale of SDQ, reported by parents B4 School Check 
Prosocial behavior 
(teacher-reported) 
Subscale of SDQ, reported by parents B4 School Check 
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CHAPTER 4 – MANUSCRIPT 1: COMPARATIVE EFFECTIVENESS OF METFORMIN 
VERSUS INSULIN FOR INITIAL TREATMENT OF GESTATIONAL DIABETES: 
MATERNAL AND NEONATAL OUTCOMES 
4.1 Introduction 
Gestational diabetes mellitus (GDM) is characterized by relative insulin deficiency 
that leads to maternal hyperglycemia (2). Worldwide, an estimated 1 in 7 births are affected 
by GDM (2). Identification and treatment of GDM improves perinatal outcomes (12, 14, 70). 
While many GDM women are able to achieve euglycemia with lifestyle interventions (diet 
and exercise), an estimated one-third of GDM women require pharmacologic treatment to 
maintain euglycemia (15, 71). When women fail to achieve euglycemia with lifestyle 
interventions, the optimal pharmacologic agent for GDM treatment is unclear. 
Historically, injectable insulin has been the standard GDM treatment. Newer data 
suggest that oral hypoglycemic agents (OHAs) such as metformin may be an acceptable 
alternative to insulin to treat GDM. The evidence for the comparative effectiveness of OHAs 
versus insulin, however, is limited and inconclusive (41, 46, 48-52, 54-56, 72). The most 
recent Cochrane review could not recommend nor refute use of OHAs for GDM treatment 
based on available evidence (110). 
To date, there have been no large observational studies evaluating the comparative 
effectiveness of metformin versus insulin. GDM treatment with metformin has been 
endorsed by the numerous professional and governmental organizations (7, 10, 62), yet 
guidelines caution that the safety of metformin use during pregnancy is not yet established 
and emphasize the need for more information on the effects of OHA for GDM treatment. To 
address this, the objective of this study was to estimate the comparative effectiveness of 
 36 
metformin versus insulin in a large cohort study using routinely collected health care data 
from New Zealand. 
4.2 Methods 
4.2.1 Study population 
The New Zealand Ministry of Health maintains 20 District Health Boards for the 
purpose of funding, planning, and providing health services. Because health services in New 
Zealand are funded by the government, eligible persons receive free inpatient and 
outpatient public hospital services, including pregnancy services and subsidies on 
prescription items.  Nationally, approximately 14 repositories of health information exist and 
are linkable through a National Health Identifier (NHI), including the Pharmaceutical Claims 
Data Mart (PHARMS) and the National Minimum Dataset (NMDS) for hospitalizations (111). 
We identified a retrospective cohort of pregnancies with deliveries occurring in New Zealand 
between 2005 and 2015. Pregnancies were identified using the National Maternity 
Collection (MAT) which provides information on primary maternity services from the first 
midwife encounter through the postpartum period. This includes information from midwife 
encounters and hospitalizations. Mothers and infants are linked via a unique pregnancy key. 
Because stillbirths are not reliably reported in MAT, we linked available mortality data from 
years 2005 to 2013 to more accurately classify infant birth outcomes.  
We estimated the start of pregnancy using gestational age as reported in MAT. 
Gestational age in MAT is reported as either the duration of completed weeks between a 
woman’s self-reported last menstrual period (LMP) date and her delivery date, or derived 
from a clinical assessment during pregnancy or at birth. For those missing gestational age 
but having a recorded date of LMP, we estimated gestational age by calculating the number 
of completed weeks from the LMP to the delivery date. If both LMP and gestational age 
were missing, we removed these deliveries from our cohort.  
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We used the estimated start of pregnancy to define our baseline period for 
covariates. We examined the healthcare history for each pregnancy using data from 
hospitalizations, pharmaceutical claims and maternity care from 6 months prior to the 
estimated start of pregnancy through the start of the GDM screening and diagnosis window 
of time, 24-28 weeks gestation. To augment missing data on demographic characteristics, 
we linked the National Health Index (NHI) dataset to MAT. The NHI contains basic 
demographic information on NZ residents, including date of birth, residence, ethnicity, 
resident status, and socioeconomic status via the New Zealand Deprivation Index 
(NZDep13). The NZDep13 is an index of social deprivation that ranges from 1 to 10, where 
1 represents the areas with the least deprived scores and 10 the areas with the most 
deprived scores (107). These data are updated on individuals at the time of a hospital 
encounter. Infants are registered with the NHI at birth. 
In New Zealand, according to national guidelines, women are first screened for 
gestational diabetes with the “post-polycose” glucose tolerance test (10, 112). If the value of 
this test is ≥7.8 mmol/L they will undergo the oral glucose tolerance test and diagnosed with 
GDM if the fasting test result is ≥5.5mmol/L or the 2-hour test result is ≥9.0mmol/L. 
Following diagnosis of GDM, New Zealand women are provided with a blood glucose meter 
for home-based glucose testing and are given a prescription for testing strips (personal 
communication, Lesley MacLennan, Counties Manukau District Health Board). Because 
these prescriptions are subsidized by the NZ government, claims are filed for payment to the 
NZ Pharmaceutical Management Agency (PHARMAC) and recorded in the PHARMS 
collection. We considered a claim for prescription blood glucose test strips to be evidence of 
a GDM diagnosis in each pregnancy if the first prescription was filled after the start of the 
GDM screening period, 24 weeks gestation. If a prescription for test strips was filled anytime 
during the lookback period (6 months prior to pregnancy through 24 weeks gestation), we 
considered this to be evidence of prior type 2 diabetes and excluded these pregnancies. We 
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used a shorter lookback period (3 months prior to pregnancy) for women with closely 
spaced pregnancies. This was done to avoid excluding pregnancies immediately following a 
pregnancy complicated by GDM and beginning less than 6 months after the prior delivery. 
We also examined claims for antidiabetic medications (insulin, metformin, glibenclamide, 
glipizide, glicazide, pioglitazone, and acarbose) and excluded women who had a 
prescription claim for any antidiabetic prior to 24 weeks gestation.  
Pharmaceutical data from the PHARMS are reliably available from 2005 onwards. 
Thus, in order to ensure that we observed the full 6-month lookback history of prescription 
use for each pregnancy, we restricted our cohort to pregnancies with an estimated start date 
of June 30, 2005 or later. We further restricted our cohort to pregnancies with a duration of 
20 weeks or greater, and to infants weighing at least 400 grams. We additionally excluded 
pregnancies if the mother was younger than 15 years old at delivery, or older than 45 years 
old. Finally, we excluded pregnancies with missing information on gestational age.  After 
identifying pregnancies with GDM, we identified prescriptions filled after or just before (one 
week or less) the first prescription for a blood glucose test strip. Our cohort was then 
narrowed down to women who initiated metformin, insulin, or both on a given date (Figure 
1).  
4.2.2 Exposure definition 
For women who received both metformin and insulin during their pregnancy for the 
first time after filling a test strip prescription, we defined “combination therapy” as a 
dispensing for both medications within 7 days of the first claim. We treated combination 
therapy co-initiators as a separate group, as the need for both medications may have 
indicated an additional degree of GDM severity. For our primary analyses, we restricted our 
study population to pregnancies initially treated with metformin or insulin monotherapy. A 
woman who later added another therapy (>7 days after the first claim) remained in the 
cohort and analyzed as part of the treatment group with which she started.   
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4.2.3 Outcome definitions 
Maternal outcomes (elective and emergency caesarean-sections, induction, 
preeclampsia and severe perineal trauma) were identified from the MAT dataset and derived 
from ICD-10-AM diagnosis codes from the NMDS collection of hospitalization events. For 
infants, outcomes of interest from the MAT dataset included birthweight and preterm birth. 
For delivery event outcomes not reported in MAT (neonatal hypoglycemia, shoulder 
dystocia, and respiratory distress) we used ICD-10-AM diagnosis codes recorded in NMDS 
during the delivery event in the hospital. We defined neonatal intensive care unit (NICU) 
admission by a hospitalization event in NMDS hospitalization event with a health specialty 
code for a Level II or Level III neonatal intensive care unit. A small proportion (<1%) of 
mothers and infants were missing records in hospitalization data, and were excluded from 
analyses comparing outcomes that were not available from MAT. Information on stillbirths 
were derived from the both the MAT and Mortality Data Collections and used as an outcome 
in our analysis. We estimated sex-, gestational age-, and ethnicity-specific birthweight 
percentiles from a sample of New Zealand infants born between 2001 and 2015 and 
recorded in MAT (N=850,506) to estimate risk of large-for-gestational-age.  
4.2.4 Covariates 
We identified potential confounders of the relationship between GDM treatment and 
infant birthweight from the relevant literature and based on clinical knowledge. We focused 
on infant birthweight as the outcome most directly-related to the effectiveness of these 
medications, and a contributing factor to other adverse outcomes such as macrosomia, 
severe perineal trauma or shoulder dystocia. Potential confounders included maternal age, 
maternal ethnicity, maternal socioeconomic status as determined by the NZ Deprivation 
Index, maternal BMI, maternal smoking status, prior history of GDM (treated and untreated), 
and timing of GDM diagnosis and treatment. We also examined claims for laboratory tests 
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from community laboratories to determine which screening and diagnostic tests were 
commonly received in our cohort.  
4.2.5 Statistical analysis 
We used multiple imputation using chained equations to estimate values of BMI, 
smoking status, and parity for pregnancies missing this information (108). BMI was 
measured at the first encounter with a Lead Maternity Carer in New Zealand, which means 
some women may have had their BMI recorded late in pregnancy. We reassigned extreme 
BMI values (<14 and >72) to missing. We then used multiple imputation to estimate BMI for 
pregnancies with missing data, including reassigned extreme values. We similarly imputed 
values for smoking status (yes/no), maternal ethnicity, and parity (0, 1, 2, or 3 or more prior 
births) at the time of the first LMC encounter.  
To control for identified covariates, we estimated propensity scores for each 
pregnancy, calculated as the estimated probability of treatment with metformin versus insulin 
for each pregnancy conditional on measured covariates using logistic regression. We then 
used these values as inverse probability of treatment weights (IPTW), calculated as the 
inverse of probability of receiving the treatment actually received. Assuming no unmeasured 
confounders, estimated treatment effects from an IPTW analysis can be interpreted as the 
average treatment effect in the study population (113). We assessed balance of covariates 
pre- and post-weighting by calculating standardized mean differences for individual 
covariates for comparison and judged balance to be adequate if standardized mean 
differences post-weighting were less than 0.05. To measure the association between 
treatment with metformin versus insulin and the maternal and infant outcomes listed above, 
we estimated risk ratios and risk differences with 95% confidence intervals. Because some 
women contributed multiple pregnancies to our study cohort, we used generalized 
estimating equations for repeated measures to control for within-woman correlations. These 
models assumed an independent correlation structure, as is recommended with models 
 41 
weighted using IPTW (109). We also included geographic region as a covariate in outcome 
models. 
We conducted sensitivity analyses to estimate the comparative effectiveness of 
metformin versus insulin in key subgroups. We estimated unadjusted and weighted risk 
ratios and risk differences stratified by ethnicity. We conducted a sensitivity analysis 
restricting deliveries to those occurring after 2008, following the publication of the landmark 
MiG trial. Finally, we conducted an analysis of infant outcomes stratified by sex to explore a 
possible biological interaction between treatment and sex. This study was approved by the 
New Zealand Health and Disability Ethics Committee (Reference 16/NTA/66) and by the 
University of North Carolina at Chapel Hill Institutional Review Board (16-1121). 
4.3 Results 
We identified 679,125 deliveries occurring in New Zealand and recorded in MAT 
between 2005 and 2015 (Figure 4.1). Among these deliveries, 669,174 were singleton 
births. We were able to link mothers and infants in 662,290 pregnancies total. We eliminated 
pregnancies that were estimated to have begun earlier than June 30, 2005 (n=71,554), 
those missing gestational age (n=1,490), mothers aged less than 15 or over 45 years old 
(n=988), infants with a birthweight less than 400g (n=219), and infants born prior to 20 
weeks gestation (n=105). From the 588,034 pregnancies meeting the inclusion criteria, we 
identified 22,060 (3.8%) with a claim for diabetic testing strips prior to delivery. We further 
excluded pregnancies with evidence of diabetic test strip fills prior to 24 weeks gestation 
(n=6,580), as this may be more indicative of overt diabetes than incident GDM.  Of the 
15,480 pregnancies assumed to have incident GDM based on diabetic test strip fill timing, 
8,249 (53.3%) initiated a prescription for metformin or insulin after or shortly prior to 
obtaining test strips. We identified 981 pregnancies with metformin and insulin initiated 
concomitantly (separate fills within 7 days), 3,818 pregnancies with initiated metformin, and 
3,450 pregnancies with initiated insulin.  
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 Women who initiated metformin or insulin monotherapy were similar with respect to 
maternal characteristics including age, smoking status, and BMI (Table 4.1). On average, 
women were approximately 32 years old and had an average BMI of 29 prior to treatment 
for GDM. We observed substantial differences in other characteristics such as geographic 
region, ethnicity, and NZDep13 scores. The majority of metformin-treated pregnancies 
(62%) were from women in the Northern region. The prevalence of insulin treatment was 
more spread out geographically, with 34% of insulin-treated pregnancies in the Northern 
region and 24% on the South Island. We also observed trends in use by ethnicity. With 
regard to ethnicity, over half (57%) of insulin-treated pregnancies were among women of 
European ethnicity, while the majority (61%) of metformin-treated pregnancies were among 
women who identified as Asian or Pacific Peoples ethnicity. Additionally, pregnancies 
treated with metformin were more likely to be among women of lower socioeconomic status 
according to the NZDep13. Approximately 9% of insulin-treated pregnancies were among 
women assigned a score of 10 (indicating most deprivation) while 19% of metformin-treated 
pregnancies belonged to women with that score. We found evidence of diabetic screening 
or diagnostic tests (Hba1c, fructosamine, oral glucose tolerance test or serum glucose test) 
in over 90% of pregnancies. Only approximately 50% of pregnancies had a laboratory claim 
for the screening post-polycose test, though over 80% received the diagnostic oral glucose 
tolerance test. Roughly 60% of pregnancies were registered for prenatal care with a Lead 
Maternity Carer (e.g., midwife, obstetrician, or general practitioner) in the first trimester. 
Approximately 12% of women who initiated metformin required supplemental insulin, while 
just 1% of insulin initiators required supplemental treatment with metformin.   
 We observed time-based trends in treatment over the course of the study period. 
Very few pregnancies (n=29, 6%) were treated with metformin pre-2008, compared with 444 
insulin-treated pregnancies (94%). This changed dramatically in 2008, when the number of 
metformin-treated pregnancies more than doubled between 2008 (33%) and 2009 (56%).    
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 Our study cohort contained 634 women diagnosed with GDM in a prior pregnancy 
according to our study definition, while 405 of these women also received metformin or 
insulin treatment during the affected prior pregnancy. History of diagnosed and treated GDM 
was more common among the insulin treatment group. Both treatment groups had a median 
gestational week of diagnosis of week 30 (IQR 28, 32), and the median gestational week of 
treatment was week 32 (IQR 30, 34). After weighting, we observed no substantial 
differences in measured covariates between treatment groups (Appendix 3). 
 Before and after adjustment with IPTW compared to insulin, metformin use was 
associated with a reduced risk of elective c-section delivery and induction (Table 4.2). We 
did not observe differences in the risk of emergency c-section, preeclampsia or severe 
perineal trauma between treatment groups. Among infants, we observed similar birthweights 
and no meaningful difference in the risk of macrosomia associated with metformin compared 
with insulin use. The risk of large-for-gestational-age and neonatal hypoglycemia were 
significantly reduced in metformin-treated pregnancies compared with insulin. Shoulder 
dystocia was rare overall, yielding imprecise estimates, though the magnitude of the 
estimates suggests no substantial differences in risk associated with metformin versus 
insulin use. Stillbirths were extremely rare (n=8) and estimates of the association of 
treatment with stillbirth are not reported. The risk of NICU admission after birth was less 
common among metformin-exposed infant, with an attenuated effect after adjusting (RD= -
15.4, 95% CI -17.2, -13.6 pre-weighting, RD= -5.9, 95% CI -7.5, -4.3 post-weighting). We 
further examined hospital discharge dates for mothers and infants and observed that 
pregnancies treated with metformin were less likely to result in an extended hospitalization 
for the infant, defined as an infant being discharged after the mother, compared with insulin 
(RD= -2.3, 95% CI -3.4, -1.2). We also observed a decrease in risk of preterm birth (defined 
as fewer than 37 completed weeks of gestation) associated with metformin use compared 
with insulin (RD= -1.7, 95% CI -3.0, -0.3). 
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 In our cohort, we observed minor differences in effect estimates by ethnicity in our 
cohort (Figure 4.2, Appendix 4). The risk difference estimates for the association of 
metformin versus insulin treatment and elective c-section varied from 1.7 (95% CI -3.4, 6.7) 
among mothers who identified as Pacific Peoples to -5.7 (95% CI -10.3, -1.2) among Māori 
mothers. The effect estimates for neonatal outcomes were largely similar in magnitude and 
direction among infants born to mothers who identified as European, Māori, or Pacific 
Peoples. With respect to maternal and neonatal outcomes, among Asian women, metformin 
and insulin appeared to be equivalent. There was a reduced risk of neonatal hypoglycemia 
associated with metformin use compared with insulin among women who identified as 
European, Māori, or Pacific Peoples, but not among Asian women. In our sensitivity analysis 
examining outcomes among deliveries occurring after 2008, we observed risk ratios and risk 
differences similar to the overall cohort (Appendix 5).  
 Based on the results of our sex-specific analyses, metformin treatment for GDM was 
associated with a greater reduction in risk for neonatal hypoglycemia compared to insulin 
among boys (RD= -6.3, 95% CI -9.0, -3.7) than among girls (RD= -2.0, 95% CI -4.8, 0.8) 
(Appendix 6).  Similarly, metformin appeared to reduce the risk of large-for-gestational-age 
to a greater extent among boys (RD= -4.8, 95% CI -7.3, -2.3) than among girls (RD= -2.0, 
95% CI -4.8, 0.8) compared to insulin. For other neonatal outcomes, risk difference 
estimates were similar in direction and magnitude for both boys and girls. 
4.4 Discussion 
In a population-based cohort of NZ pregnancies treated pharmacologically for GDM, 
we did not observe increased risks of adverse maternal or neonatal outcomes associated 
with metformin use compared with insulin. Initial treatment with metformin was associated 
with reduced risks of elective c-section, labor induction, infant macrosomia, neonatal 
hypoglycemia, and preterm birth. Our estimates for rare adverse outcomes such as 
preeclampsia and shoulder dystocia do not suggest major differences in risk of these events 
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among metformin and insulin users. While rare, our confidence intervals for these 
associations were more precise than the combined estimates from a recent meta-analysis 
(52) (Appendix 7). In stratified models, we observed variation in elective c-section estimates 
by ethnicity, as well as variation in the degree to which metformin use affected neonatal 
hypoglycemia risk. We also observed variation by infant sex in the risk difference estimates 
for the association of metformin versus insulin treatment and two outcomes, neonatal 
hypoglycemia and large-for-gestational-age.  
 Our findings are consistent with results from the MiG trial and from a previous 
observational study in New Zealand (41, 54). The most recent meta-analysis of trials 
comparing metformin to insulin also calculated a summary estimate showing reduced risk of 
neonatal hypoglycemia associated with metformin (52).  Similarly to an observational study 
conducted in the Auckland region, we observed a reduced incidence of NICU admission 
was associated with metformin versus insulin (54). 
 We observed potential differences by infant sex in how effective metformin is 
compared with insulin for preventing neonatal hypoglycemia and being large-for-gestational-
age. Emerging research suggests that there may be clinically important differences in how 
men and women respond to diabetic therapies (114, 115).However, there is no information 
on how diabetic therapies used during pregnancy may differentially affect male and female 
fetuses. Our data suggest that further research on sex-specific effects of different GDM 
pharmacotherapy is needed.   
 Our study has a number of strengths. We studied over 7,000 treated pregnancies 
using routinely-collected healthcare data from the New Zealand Ministry of Health. This 
allowed us to compare metformin versus insulin in key subgroups, including stratifying 
models by ethnicity and infant sex. Additionally, the MAT data collection offered a unique 
opportunity to link information collected as part of maternity care with pharmaceutical 
dispensing, hospitalizations, laboratory claims and demographic data. We were able to 
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measure potential confounders such as maternal BMI, parity, smoking status, and 
socioeconomic status. We were also able to restrict our cohort to women with GDM 
diagnosed after 24 weeks of pregnancy. This represents an important improvement over 
other pharmacoepidemiological studies of treatment in pregnant women, which often must 
assume gestational age based on delivery diagnostic and procedure codes, and may restrict 
their populations to live births only (57, 58). 
 The use of secondary data presents some limitations. The MAT data collection only 
contains information on BMI recorded during the first encounter with a Lead Maternity Carer, 
which may have occurred in the second or third trimester. This means that the BMI 
measurement in MAT may not match a woman’s BMI prior to pregnancy. However, 
approximately 60% of women in our cohort registered with a Lead Maternity Carer in the first 
trimester during which weight changes are typically minimal. We used multiple imputation 
using chained equations to overcome this limitation. Other limitations include missing 
information on weight gain during pregnancy and infant laboratory test results, limiting our 
ability to examine gestational weight gain as a confounder or confirm neonatal hypoglycemia 
as an outcome.  As a strength, our treatment groups were already well-balanced by the 
active comparator new user design (116, 117). This is demonstrated by how stable our 
estimates were pre- and post-adjustment.  
 Overall, we observed no substantial differences in effectiveness between metformin 
and insulin as treatment for GDM based on a wide array of clinically relevant maternal and 
child outcomes. Metformin appears to be associated with reduced risks of neonatal 
hypoglycemia and NICU admission, which has been previously shown in randomized trials. 
We observed no clinically significant differences in average birthweight between the two 
treatment groups. Our data, as well of that of two recent meta-analyses show that metformin 
may have positive effects on GDM-treated women and infants (52, 53). While reassuring,   
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there is still inconclusive evidence for long-term infant safety following in utero exposure to 
metformin. Longitudinal research on child health outcomes from children exposed to 
metformin in utero is still needed. 
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4.5 Tables and Figures 




Table 4.1 Initial demographic and clinical characteristics of New Zealand pregnancies 





 N % N % 
Maternal age (Mean, SD) 31.9 5.4 32.4 5.4 
Maternal age (Median, IQR) 33 29, 36 32 28, 36 
BMI (kg/m2) (Mean, SD)a 29.4 7.6 29.2 8.4 
BMI (kg/m2) (Median, IQR)a 28 23, 33 28 24, 33 
Gestational Week of Diagnosis 
(Mean, SD) 30.5 2.9 30.1 2.9 
Gestational Week of Diagnosis 
(Median, IQR) 30 28, 32 30 28, 32 
Gestational Week of Treatment 
Initiation (Mean, SD) 32.0 2.9 31.6 2.9 
Gestational Week of Treatment 
Initiation (Median, IQR) 32 30, 34 32 30, 34 
Maternal Age Categories     
15 - 20 74 1.9 64 1.9 
21 - 25 407 10.7 330 9.6 
26 - 30 1038 27.2 834 24.2 
31 - 35 1256 32.9 1180 34.2 
36 - 40 835 21.9 844 24.5 
41 - 45 208 5.5 198 5.7 
Geographic Region     
Northern 2382 62.4 1205 34.9 
Midland 380 10.0 715 20.7 
Central 540 14.1 690 20.0 
South Island 516 13.5 840 24.4 
Delivery Year     
2006 20 0.5 174 5.0 
2007 9 0.2 270 7.8 
2008 143 3.8 289 8.4 
2009 337 8.8 266 7.7 
2010 412 10.8 249 7.2 
2011 540 14.1 332 9.6 
2012 536 14.0 355 10.3 
2013 673 17.6 466 13.5 
2014 683 17.9 596 17.3 
2015 465 12.2 453 13.1 
Ethnicity (Prioritized)b     
European 1581 41.41 1953 56.61 
Māori 555 14.54 585 16.96 
Pacific Peoples 854 22.37 462 13.39 
Asian 1461 38.27 1002 29.04 
Other 150 3.93 112 3.25 
Ethnicity (Any, Yes)b,c     
European 1085 28.4 1468 42.6 
Māori 555 14.5 585 17.0 
Pacific Peoples 781 20.5 393 11.4 
Asian 1279 33.5 909 26.4 
Other 117 3.1 93 2.7 
 
NZ Resident (Yes)d 3453 90.7 3207 93.2 






1 (least deprived) 164 4.3 261 7.6 
2 235 6.2 252 7.3 
3 292 7.7 263 7.6 
4 276 7.2 298 8.6 
5 302 7.9 339 9.8 
6 359 9.4 335 9.7 
7 413 10.8 422 12.2 
8 407 10.7 469 13.6 
9 652 17.1 491 14.2 
10 (most deprived) 718 18.8 320 9.3 
Paritye     
0 (primipara) 1194 36.4 1214 38.8 
1 1139 34.7 1069 34.2 
2 476 14.5 475 15.2 
3 or more 474 14.4 371 11.9 
Trimester of Registrationf     
1st 2252 64.8 2132 64.8 
2nd 1009 29.0 974 29.6 
3rd 214 6.2 183 5.6 
 
Smoker at First Visit (Yes)g 268 7.9 267 9.3 
     
BMI Categoriesa     
Underweight (<18.5) 37 1.2 55 2.0 
Normal (18.5 – 24.9) 940 29.5 824 30.0 
Overweight (25 – 29.9) 878 27.6 741 27.0 
Obese (30 +) 1330 41.8 1127 41.0 
 
Prior GDM (Yes) 315 8.3 319 9.3 
Prior Treated GDM (Yes) 192 5.0 213 6.2 
aBMI values are recorded at the first prenatal care encounter. These values reflect BMI 
recorded prior to metformin or insulin initiation. BMI values were missing for 1,336 women 
(18.4%). 
b Maternal ethnicity was missing for 3 women (0.1%). The category of “Other” ethnicity 
includes Middle Eastern, Latin American/Hispanic, African, and other unspecified ethnicities. 
cThis includes any mention of a given ethnicity reported in first, second, or third ethnicity 
codes. As multiple ethnicities can be reported, proportions do not add up to 1.  
dNew Zealand resident status was missing for 21 women (0.3%).  
eParity information was missing for 856 women (11.8%).  
fTrimester of maternity care registration was missing for 317 women (6.9%).  







Table 4.2 Unadjusted and IPTW-adjusted risk ratios (RR), risk differences (RD) per 100, and 95% CI for maternal and neonatal 
outcomes comparing pregnancies treated with metformin or insulin for gestational diabetes in New Zealand, 2006-2015 






RR (95% CI) RD (95% CI) RR (95% CI) RD (95% CI) 
Elective c-section 720 (18.9) 808 (23.4) 0.81 (0.74, 0.88) -4.5 (-6.4, -2.6) 0.89 (0.81, 0.98) -2.3 (-4.3, -0.3) 
Emergency c-section 640 (18.6) 650 (17.0) 0.92 (0.83, 1.01) -1.5 (-3.3 0.2) 0.92 (0.82, 1.02) -1.5 (-3.4, 0.5) 
Induction 1965 (51.5) 1884 (54.6) 0.94 (0.90, 0.98) -3.2 (-5.5, -0.8) 0.92 (0.88, 0.97) -4.3 (-6.8, -1.8) 
Preeclampsiab 139 (3.6) 116 (3.5) 1.08 (0.85, 1.38) 0.3 (-0.6, 1.1) 1.07 (0.83, 1.39) 0.2 (-0.7, 1.1) 
Severe perineal 
traumac 
74 (1.9) 65 (1.9) 
1.03 (0.75, 1.43) 0.1 (-0.6, 0.7) 0.89 (0.63, 1.27) -0.3 (-0.9, 0.4) 







-20.69 (-46.09, 4.71)  0.58 (-27.06, 28.23)  
Macrosomiad,f 405 (10.7) 415 (12.2) 0.88 (0.77, 1.00) -1.5 (-3.0, 0.0) 0.91 (0.80, 1.06) -1.0 (-2.6, 0.6) 
Large-for-gestational-
aged,g 
549 (14.5) 653 (19.1) 
0.77 (0.69, 0.85) -4.4 (-6.2, -2.7) 0.80 (0.71, 0.89) -3.7 (-5.5, -1.8) 
Neonatal 
hypoglycemiah 
543 (14.3) 754 (22.0) 0.65 (0.59, 0.72) -7.7 (-9.5, -5.9) 0.74 (0.66, 0.82) -5.0 (-6.9, -3.2) 
Shoulder dystociab 37 (1,0) 42 (1.2) 0.80 (0.51, 1.24) -0.2 (-0.7, 0.2) 0.88 (0.55, 1.41) -0.1 (-0.7, 0.4) 
Respiratory distressh 194 (5.1) 244 (7.1) 0.72 (0.60, 0.86) -2.0 (-3.1, -0.9) 0.87 (0.71, 1.06) -1.0 (-2.2, 0.2) 
NICU admissionh,i 
458 (12.1) 962 (28.1) 0.44 (0.40, 0.49) -15.4 (-17.2, -
13.6) 
0.63 (0.57, 0.70) -5.9 (-7.5, -4.3) 
Extended postnatal 
hospitalizationb.h,j 
168 (4.4) 260 (7.6) 0.58 (0.48, 0.70) -3.2 (-4.3, -2.1) 0.69 (0.56, 0.84) -2.3 (-3.4, -1.2) 
Preterm birthk 269 (7.1) 311 (9.0) 0.78 (0.67, 0.92) -1.9 (-3.2, -0.7) 0.79 (0.67, 0.93) -1.7 (-3.0, -0.3) 
aInverse probability of treatment weights (IPTW) were estimated using a propensity score model containing the following covariates: maternal age, maternal 
ethnicity, maternal NZ deprivation decile score, parity, BMI prior to prescription initiation, smoking status, timing of GDM diagnosis and treatment, history of 
GDM and history of GDM treatment. The IPTW adjusted model uses imputed values for parity, BMI, and smoking status. These models are also adjusted for 
geographic region. 
bHospitalization data for women were missing for 39 delivery events (18 metformin, 21 insulin). 
cSevere perineal trauma is defined as third- or fourth-degree tear or a tear requiring surgical repair.  
dBirthweight values were missing for 63 infants (29 metformin, 34 insulin). 
eLinear regression was used to compare mean birthweight in infants treated initially with metformin versus insulin. 
fMacrosomia is defined as birthweight greater than 4,000g.  
gLarge-for-gestational-age is defined as a birthweight greater than the 90th percentile. These percentiles were calculated using a sample of New Zealand infants 
born between 2001 and 2015 with available data on birthweight and gestational age (n=850,506). These percentiles are additionally sex- and ethnicity-specific.  
hHospitalization data for infants were missing for 39 delivery events (18 metformin, 21 insulin).  





jExtended postnatal hospitalization was defined as an infant being discharged from the hospital after a mother was discharged following delivery.  




Figure 4.2 Ethnicity-stratified risk difference estimates and 95% confidence intervals for the 





CHAPTER 5 – MANUSCRIPT 2 
5.1 Introduction 
Gestational diabetes mellitus (GDM) is a common pregnancy complication, 
characterized by relative insulin deficiency and in most women, impaired insulin action, 
leading to hyperglycemia (2). An estimated 1 in 7 births are affected by GDM worldwide (2). 
While many women are able to control GDM through lifestyle changes, an estimated one-
third of women with GDM require pharmacologic treatment to manage their condition (15, 
118). 
  Oral hypoglycemic agents like metformin have emerged as a promising option for 
managing GDM (110). In randomized trials comparing maternal and infant outcomes at 
delivery, metformin has been shown to be an effective alternative to insulin, the historical 
standard treatment for GDM (22, 41, 46, 50). In the absence of long-term data on the safety 
of metformin use during pregnancy, concerns remain regarding the potential development 
effects that may only be evident later in childhood (7, 10, 62, 63, 71, 118).Unlike insulin, 
metformin has been shown to cross the placenta (16, 18, 19). This has caused concerns 
that metformin may impact fetal development in ways that insulin would not. 
To date, researchers have examined the comparative safety of metformin versus 
insulin treatment during pregnancy on the offspring in children up to age 4 (43-45, 47, 119). 
Although these studies have suggested no clinical differences in growth or 
neurodevelopment among the offspring of women treated with metformin versus insulin for 
GDM, they were limited by small initial sample sizes and loss-to-follow-up from the original, 
randomized study population. Thus, patients and providers remain concerned about the 
long-term effects of metformin (120). To address the noted lack of long-term safety 
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information in children of women treated with metformin or insulin during pregnancy, we 
conducted a retrospective cohort study in a New Zealand (NZ) population of treated women 
linked with their child’s growth and developmental data at age 4, taken from a pre-school 
readiness screening program provided as routine well-child care throughout NZ. 
5.2 Methods 
5.2.1 Study population 
Health services in NZ are funded by the government, meaning eligible persons 
receive free inpatient and outpatient public hospital services, including pregnancy services 
and subsidies on prescription items.  Nationally, approximately 14 repositories of health 
information exist and are linkable through a National Health Identifier (NHI) (73). We 
identified a cohort of pregnancies with deliveries occurring in NZ between 2005 and 2012. 
Pregnancies were identified using the National Maternity Collection (MAT) which provides 
information on primary maternity services from the first prenatal encounter through the 
postpartum period. Mothers and their children were linked via a unique pregnancy key. 
Gestational age in MAT was reported as either the duration of completed weeks between a 
woman’s self-reported last menstrual period (LMP) date and her delivery date, or derived 
from a clinical assessment during pregnancy or at birth. For those missing gestational age 
but having a recorded LMP date, we estimated gestational age by calculating the number of 
completed weeks from the LMP date to the delivery date. We estimated the start of 
pregnancy using gestational age as reported in MAT.  
We examined the healthcare history for each pregnancy using data from 
hospitalizations, pharmaceutical claims and maternity care from 6 months prior to the 
estimated start of pregnancy through the start of the GDM screening and diagnosis window 
of time, 24-28 weeks gestation. Additional demographic characteristics were obtained 
through linkage to the National Health Index, which contains basic demographic information 
on NZ residents, including date of birth, residence, ethnicity, resident status, and 
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socioeconomic status via the NZ Deprivation Index (NZDep13). The NZDep13 is an index of 
social deprivation that ranges from 1 to 10, where 1 represents the areas with the least 
deprived scores and 10 the areas with the most deprived scores (107). These data are 
updated on individuals at the time of a hospital encounter. Infants are registered with the 
NHI at birth. 
5.2.2 Exposure definition 
In NZ, women diagnosed with GDM are first screened with the “post-polycose” 
glucose tolerance test (10, 112). According to national guidelines, if the value of this test is 
≥7.8 mmol/L, patients undergo the oral glucose tolerance test and are diagnosed with GDM 
if the fasting test result is ≥5.5mmol/L or the 2-hour test result is ≥9.0mmol/L. Following 
diagnosis of GDM, NZ women are provided with a blood glucose meter for home-based 
glucose testing and are given a prescription for testing strips (personal communication, 
Lesley MacLennan, Counties Manukau District Health Board). Because these prescriptions 
are subsidized by the NZ government, claims are filed for payment to the NZ 
Pharmaceutical Management Agency (PHARMAC) and recorded in the Pharmaceutical 
Claims Data Mart (PHARMS). We considered a claim for prescription blood glucose test 
strips to be evidence of a GDM diagnosis in each pregnancy if the first test strip claim 
appeared after the start of the GDM screening period, 24 weeks gestation. If a prescription 
for test strips was filled anytime between 6 months prior to pregnancy through 24 weeks 
gestation, we considered this to be evidence of prior type 1 or 2 diabetes and excluded 
these pregnancies. We used a shorter window (3 months prior to pregnancy) for women with 
closely spaced pregnancies. This was done to avoid excluding pregnancies immediately 
following a pregnancy complicated by GDM and beginning less than 6 months after the prior 
delivery. We also examined claims for antidiabetic medications (metformin, insulin, 
glibenclamide, glipizide, glicazide, pioglitazone, and acarbose) and excluded women who 
had a prescription claim for any antidiabetic prior to 24 weeks gestation.  
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Pharmaceutical data from the PHARMS are reliably available from 2005 onwards. 
Thus, in order to ensure that we observed the full 6-month lookback history of prescription 
use for each pregnancy, we restricted our cohort to pregnancies with an estimated start date 
of June 30, 2005 or later (Figure 5.1). We further restricted our cohort to pregnancies with a 
duration of 20 weeks or greater, and to infants weighing at least 400 grams. We excluded 
pregnancies if the mother was younger than 15 years old or older than 45 years old at 
delivery. Finally, we excluded pregnancies with missing information on gestational age.  
After identifying pregnancies with GDM, we identified prescriptions filled after or just before 
(one week or less) the first claim for a blood glucose test strip. We excluded women who 
initiated any prescription other than insulin or metformin. For women who received both 
metformin and insulin during their pregnancy for the first time after filling a test strip 
prescription, we defined “combination therapy” as a dispensing for both medications within 7 
days of the first claim. For our analyses, we restricted our study population to pregnancies 
initially treated with metformin or insulin monotherapy.  
5.2.3 Outcome definitions 
The B4 School Check (B4SC) is a universal health and development screening 
program offered to all children in NZ at age 4 as part of routine well-child care, prior to 
school entry at age (121). This includes growth surveillance involving height and weight 
measurement and identification of behavioral problems using the Strengths and Difficulties 
Questionnaire (SDQ) for parents and teachers (SDQ-P and SDQ-T) (101, 102). We linked 
children with available results to the mothers we identified as initiating metformin or insulin 
treatment for GDM. 
5.2.3.1 Growth outcomes 
We used height and weight values from the B4SC to calculate child BMI. These 
values were also used to estimate z-scores and percentile-based outcomes for weight, 
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height, weight-for-height, and BMI. We used the 2006 World Health Organization (WHO) 
reference standards to calculate z-scores and percentiles (100). We used the 85th 
percentile as a cutpoint for defining overweight and obesity in children and applied this 
cutpoint for creating dichotomous outcomes for each growth measurement. We also 
examined the proportion of children with weight, height, weight-for-height and BMI z-scores 
≥1 or ≥2. Additionally, the B4SC recommends referral for children with weight above the 
97th percentile and BMI of 21 or over (99). We therefore used the 97th percentile as a 
cutpoint for extreme growth measurements and examined the proportion of children with a 
BMI measurement of 21 or over.  Details on how practitioners are instructed to take weight 
and height measurements during the B4SC can be found in the program’s handbook (99). 
5.2.3.2 Strengths and Difficulties Questionnaire 
The B4 School Check offers screening to help identify children that may need help 
with learning and development before entering school using the SDQ (102). The SDQ is 
designed to assess the child’s strengths in five subscales pertaining to different emotions or 
behaviors: prosocial behavior, hyperactivity, emotional symptoms, conduct, and peer 
problems (101, 102). In NZ, the SDQ was offered in two different formats, depending on 
whether a parent or a teacher is administering the questionnaire. Parents and teachers 
respond “not true”, “somewhat true”, or “certainly true” to each statement pertaining to the 
child’s behavior (e.g., “Considerate of other people’s feelings”, “Often loses temper”). 
Responses to these statements can be organized into the four subscales of hyperactivity, 
emotional symptoms, conduct, and peer problems. Scores from these subscales are 
summed to result in a Difficulties Score which can range from 0 to 40, with higher scores 
indicating concern and possible need for referral (99, 105). The cut-off for a “concerning” 
score is typically 17 for the parent-completed SDQ and 16 for the teacher-completed SDQ; 
however, a review of the SDQ in the NZ population found that a lower cut-off is more 
appropriate (14 for SDQ-P, 11 for SDQ-T) (99, 105). An additional prosocial behavior scale 
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is not included in the total Difficulties Score and is scored so that an absence of prosocial 
behavior (e.g. helping, sharing) receives a lower score. 
5.2.4 Maternal and infant characteristics 
We identified potential confounders of the relationship between GDM treatment and 
child growth and development from the relevant literature and with clinical insight. In our 
study, we included maternal age, maternal ethnicity, maternal socioeconomic status as 
determined by the NZ Deprivation Index (NZDep13), maternal BMI, maternal smoking 
status, prior history of GDM (treated and untreated), and timing of GDM diagnosis and 
treatment as potential confounders. We used maternity care and hospitalization data to 
examine children’s history of infant outcomes that have been associated with child obesity 
or neurodevelopmental difficulties, such as large-for-gestational-age and neonatal 
hypoglycemia (39, 40, 122). However, because these outcomes occurred after the mother 
initiated treatment with metformin or insulin, we limited this examination to a descriptive 
analysis, rather than including infant health outcomes as covariates. 
Multiple imputation using chained equations was used to estimate missing covariate 
information (108). BMI was measured at the first prenatal care encounter in NZ, which 
means some women may have had their BMI recorded late in pregnancy. We reassigned 
extreme BMI values (<14 and >72) to missing. We then used multiple imputation to estimate 
BMI for pregnancies with missing data, including reassigned extreme values. We similarly 
imputed values for maternal ethnicity, smoking status (yes/no) and parity (0, 1, 2, or 3 or 
more prior births) at the time of the first LMC encounter.  
5.2.5 Statistical analysis 
To control for identified covariates, we estimated propensity scores for each 
pregnancy, calculated as the estimated probability of treatment with metformin based on 
measured covariates using logistic regression. We then used these values to estimate 
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inverse probability of treatment weights (IPTW), calculated as the inverse of the probability 
of receiving the treatment actually received (113). We assessed balance of covariates pre- 
and post-weighting by calculating standardized mean differences for individual covariates for 
comparison.  
For continuous outcomes (e.g. weight z-scores), we used linear regression to 
compare outcomes between children of metformin- and insulin-treated pregnancies. Log-
binomial regression was used to estimate risk ratios and 95% confidence intervals for binary 
outcomes (e.g. weight above the 97th percentile for age). Because some women 
contributed multiple pregnancies to our study cohort, we used generalized estimating 
equations for repeated measures to control for within-woman correlations. We also included 
geographic region as a covariate in outcome models. 
We conducted a sensitivity analysis to estimate the association of initiating metformin 
versus insulin with child growth and development stratified by child sex to explore a potential 
interaction observed in other clinical settings (114, 115). This study was approved by the NZ 
Health and Disability Ethics Committee (Reference 16/NTA/66) and by the University of 
North Carolina at Chapel Hill Institutional Review Board (16-1121). 
5.3 Results 
We identified 501,672 deliveries occurring in New Zealand and recorded in MAT 
between 2005 and 2012 (Figure 5.1). We excluded deliveries of multiple gestations 
(n=7,403) and further excluded pregnancies that were estimated to begin before June 30, 
2005 (n=42,758), pregnancies missing gestational age (n=1,204), mothers aged less than 
15 or greater than 45 years old (n=749), infants with a birthweight less than 400g (n=141), 
and infants born prior to 20 weeks gestation (n=79). Among the pregnancies meeting the 
inclusion criteria, we identified 13,023 (3.1%) with a claim for diabetic testing strips prior to 
delivery. We excluded 4,070 deliveries for having a diabetic test strip fill prior to 24 weeks of 
gestation, suggesting overt rather than gestational diabetes. Of the 8,953 pregnancies 
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assumed to have incident GDM based on diabetic test strip fill timing, 4,318 (48.2%) initiated 
a prescription for metformin or insulin after or shortly prior to obtaining test strips. We 
identified 386 pregnancies with metformin and insulin initiated concomitantly (separate fills 
within 7 days). We included all pregnancies resulting in liveborn children that could be linked 
to the B4SC dataset. The final cohort included 1,996 pregnancies with initiated metformin, 
and 1,932 pregnancies with initiated insulin.  
Overall, women treated with either metformin or insulin were similar with respect to 
age, BMI, and timing of GDM diagnosis and treatment initiation (Table 5.1). We observed 
strong trends by region and delivery year, however. Over half (66.7%) of metformin use was 
prescribed to women residing in the Northern region, which includes Auckland. Metformin 
use was infrequent (n=29) prior to 2008. We also observed differences in treatment initiation 
by ethnicity and NZ Deprivation Index Deciles, a measure of the relative socioeconomic 
deprivation of an area. After inverse probability of treatment weighting, treatment groups 
were well-balanced on measured covariates (Appendix 8). 
The children of women treated with metformin were less likely to have experienced 
neonatal hypoglycemia (14%) at birth compared with the offspring of women treated with 
insulin (23%). Children from both treatment groups were similar with respect to average 
gestational age at birth (38.2 weeks for metformin-treated pregnancies, 38.0 for insulin-
treated pregnancies) and average birthweight (3362g for metformin-treated pregnancies, 
3437g for insulin-treated pregnancies).  
When comparing growth outcomes (weight, height, weight-for-height and BMI) 
between children of women treated with metformin or insulin, we did not observe significant 
differences in adjusted models (Table 5.2). The average weight z-score for both groups was 
0.7 and we observed no difference in weight z-scores in our adjusted linear regression 
model (β= -0.028, 95% CI -0.125, 0.069). We compared the proportion of children with 
weights, heights, weight-for-length and BMI values at or above the 85th percentile and found 
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no significant differences in risk of these outcomes (Table 5.3). Children of metformin-
treated mothers were not significantly more likely to be ≥85th percentile for weight (adjusted 
risk ratio [aRR]=1.04, 95% CI 0.93 1.16) or weight-for-height (aRR=0.92, 95% CI 0.83, 1.02) 
than children of insulin-treated mothers. Overall, we consistently observed adjusted risk 
ratios below the null for weight, weight-for-length, and BMI outcomes, though the confidence 
intervals crossed the null. For height, we observed risk ratios to suggest that children of 
metformin-treated pregnancies may be taller on average than those of insulin-treated 
pregnancies, but after adjustment, these values were neither clinically nor statistically 
significant.  
Children born to metformin- and insulin-treated pregnancies had similar average 
SDQ-P and SDQ-T scores (Table 5.2). Less than half of the children in our study had a 
completed SDQ-T (n=1,681, 42.8%), while approximately 80% had a completed SDQ-P. 
SDQ-P and SDQ-T Prosocial Behaviour Scores were, on average, similar in both groups. 
We also observed similar proportions of concerning SDQ-P and SDQ-T Difficulties Scores 
between treatment groups. After weighting, children born to metformin-treated women 
appeared to be at an increased risk of having a concerning SDQ-P score (aRR=1.13, 95% 
CI 0.88, 1.46). However, we did not observe meaningful differences in average SDQ-P 
scores in our linear regression models after adjustment (β= -0.015, 95% CI -0.147, 0.118). 
In sex-specific models (Table 5.4), we observed differences in adjusted models for growth 
outcomes between boys and girls. The risk of having an extreme weight-for-length z-score 
(≥2) was lower among metformin-exposed boys, but higher among metformin-exposed girls 
compared with those exposed to insulin (aRR for boys=0.77, 95% CI 0.59, 1.00; aRR for 
girls=1.08, 95% CI 0.78, 1.49) (Appendix 10). However, the corresponding p-value for 
interaction (p=0.3653) indicated that these differences were not statistically significant 
(Table 5.4). Having a concerning Difficulties Score on the SDQ-P or SDQ-T was overall 
more common among boys than girls. We observed no association between metformin 
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versus insulin treatment and concerning SDQ-P scores for girls (aRR=1.00, 95% CI 0.63, 
1.58), while the risk of a concerning SDQ-P score for metformin-exposed boys was higher 
than for insulin-exposed boys (aRR=1.21, 95% CI 0.89, 1.64) (Table 5.4).  
5.4 Discussion 
In a population-based cohort of children born to women treated with metformin or 
insulin for GDM in NZ, we did not observe meaningful differences in child growth or 
developmental outcomes at age 4. Children whose mothers were treated initially with 
metformin versus insulin to manage GDM were similar with respect to weight, height, and 
BMI and we did not observe statistically or clinically significant differences between them 
after adjusting for measured covariates. We observed variation in model estimates by child 
sex, but there was not a statistically significant interaction between treatment and sex.  
As expected, the average height, weight, and BMI values for the population of children born 
to women treated pharmacologically for GDM were higher than average values for the entire 
NZ population (98). Studies have shown that maternal hyperglycemia is associated with 
obesity in children (32), though these results have been inconsistent and may be partially 
explained by maternal prepregnancy BMI (30, 31).  
Our findings are consistent with prior studies focused on child health outcomes at 
younger ages. A follow-up study of offspring born to women enrolled in the MiG trial (N=323) 
found that children who had been exposed to metformin in utero did not differ from children 
exposed to insulin with regard to weight, height, or abdominal fat at two year of age (43). 
The results of this study suggested that treatment with metformin may be associated with 
the development of less visceral fat in offspring as compared with insulin, which we were 
unable to ascertain in this observational study. At 18-months post-randomization, Ijäs et al 
reported increased risks of having a height or weight at or above the 95th percentile for 
metformin-exposed children, but the sample was small (n=93.) Thus, the estimates were 
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imprecise (e.g., weight ≥ 95th percentile RR=5.33, 95% CI 0.65, 43.91) (47), making it 
impossible to rule out a large range of possible effect sizes. 
Previous follow-up studies have also found no differences between children born to 
mothers treated with metformin versus insulin with respect to neurodevelopmental 
outcomes. A subsequent follow-up of children born to MiG trial participants at age 2 found 
no meaningful differences in Bayley Scales of Infant Development Scores by treatment 
status, though they did observe differences by country (New Zealand versus Australia) (45). 
Similarly, Terrti et al did not find differences in average Bayley-III scores between children at 
age 2 born to mothers participating in a trial comparing metformin and insulin treatment for 
GDM in Finland (119). Ijäs et al also concluded that metformin was not associated with 
developmental delay compared with insulin when comparing developmental milestones like 
standing, walking, and speech at 18 months (47). 
This study had some limitations, primarily stemming from missing data. Outcome 
measurements were missing for approximately 20% of children. We were also missing 
important covariate data for mothers, including BMI, smoking status, and parity. Using 
multiple imputation, we were able to augment the covariate data, but did not impute 
outcomes. Despite the high proportion of missing data, our study was able to examine 
outcomes in over 3,000 children, resulting in the largest study to date evaluating long-term 
outcomes in children of metformin- and insulin-treated mothers. This results in more precise 
estimates that reduce the uncertainty surrounding metformin’s impact on child development 
when used to treat GDM.  
It is possible that there may be residual confounding related to disease severity due 
to the observational nature of this study. However, the mothers included in this study were 
similar with respect to important indicators of GDM severity, such as BMI and timing of 
diagnosis. Additionally, the use of a comparative effective design helps to reduce residual 
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confounding by including exclusively women with the indication of treatment of GDM in our 
cohort and is a major methodological strength (116, 117).  
This study is the first to examine long-term outcomes beyond early childhood in 
children born to women treated with metformin versus insulin for GDM. We observed no 
meaningful differences in growth or behavioral and emotional development between 
treatment groups. This may provide clinicians and patients with important information about 
the comparative safety of metformin versus insulin when making treatment decisions during 
pregnancy.  
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5.5 Tables and Figures 
Figure 5.1 Study cohort formation 
  
 67 
Table 5.1 Demographic and clinical characteristics of New Zealand mothers treated 






N % N % 
Age (Mean, SD) 32.07 5.5 32.44 5.6 
BMI (kg/m2) (Mean, SD) 29.58 7.7 29.54 9.4 












     
Age Categories     
15 - 20 37 1.9 42 2.2 
21 - 25 209 10.5 195 10.1 
26 - 30 536 26.9 441 22.8 
31 - 35 633 31.7 638 33.0 
36 - 40 463 23.2 499 25.8 
41 - 45 118 5.9 117 6.1 
Geographic Region 
    
Northern 1331 66.7 548 28.4 
Midland 139 7.0 456 23.6 
Central 274 13.7 418 21.6 
South Island 252 12.6 510 26.4 
Maternal Ethnicity (Prioritised)a 
   
European 576 28.9 867 44.9 
Maori 290 14.5 360 18.7 
Pacific Peoples 435 21.8 243 12.6 
Asian 639 32.0 408 21.1 
Other 55 2.8 52 2.7 
Maternal Ethnicity (Any, Yes)a,b 
    
European 843 42.2 1143 59.2 
Maori 290 14.5 360 18.6 
Pacific Peoples 474 23.8 274 14.2 
Asian 736 36.9 460 23.8 
Other 75 3.8 62 3.2 
NZ Deprivation Index Deciles 
    
1 (least deprived) 89 4.5 129 6.7 
2 111 5.6 132 6.8 
3 148 7.4 133 6.9 
4 136 6.8 166 8.6 
5 154 7.7 168 8.7 
6 195 9.8 188 9.7 
7 224 11.2 239 12.4 
8 207 10.4 271 14.0 
9 362 18.1 293 15.2 
10 (most deprived) 370 18.5 213 11.0 
Delivery Year 
    
2006 20 1.0 174 9.0 
2007 9 0.5 270 14.0 
2008 143 7.2 287 14.9 
2009 336 16.8 266 13.8 
2010 412 20.6 249 12.9 







N % N % 
2012 536 26.9 354 18.3 
NZ Resident (Yes)c 1797 90.5 1794 93.2 
Parityd  
    
0 (primipara) 627 38.0 645 38.3 
1 536 32.5 545 32.3 
2 256 15.5 273 16.2 
3 or more 231 14.0 222 13.2 
Trimester of Maternity Care  
Registratione 
   
1st 1056 58.8 980 54.0 
2nd 583 32.5 710 39.1 
3rd 157 8.7 125 6.9 
Smoker at First Visit (Yes)f 114 6.6 151 10.9 
BMI (kg/m2) Categoriesg 
    
Underweight (<18.5) 16 0.8 25 1.3 
Normal (18.5 - 24.9) 442 22.1 376 19.5 
Overweight (25 - 29.9) 431 21.6 340 17.6 
Obese (30 +) 640 32.1 553 28.6 
Prior GDM (Yes) 112 5.6 135 7.0 
Prior Treated GDM (Yes) 56 2.8 84 4.4 
aMaternal ethnicity was missing for 3 women (0.1%).  
b This includes any mention of a given ethnicity reported in first, second, or third ethnicity 
codes. As multiple ethnicities can be reported, proportions do not add up to 1. The category of 
“Other” ethnicity includes Middle Eastern, Latin American/Hispanic, African, and other 
unspecified ethnicities. 
cNew Zealand resident status was missing for 18 women (0.5%).  
dParity information was missing for 593 women (15.1%).  
eTrimester of maternity care registration was missing for 317 women (8.1%).  
fSmoking status was missing for 814 women (20.7%). 
gBMI values are recorded at the first prenatal care encounter. These values reflect BMI 












Table 5.2 Unadjusted and adjusted estimates from linear regression models comparing child health outcomes between children 









Unadjusted β Estimate 
(95% CI) 
Adjusteda β Estimate (95% 
CI) 
Child Growth Outcomes     
Weight z-scoreb,c   0.7 (1.1) 0.7 (1.2) 0.012 (-0.074, 0.097) -0.028 (-0.125, 0.069)  
Height z-scorec,d  0.4 (1.1) 0.3 (1.1) 0.119 (0.044, 0.194)  0.052 (-0.034, 0.138)  
Weight-for-Lengthe z-score c 0.7 (1.3) 0.9 (1.3) -0.107 (-0.199, -0.016)  -0.095 (-0.199, 0.010) 
BMI z-scorec,e   0.8 (1.4) 0.9 (1.3) -0.097 (-0.192, -0.002)  -0.095 (-0.202, 0.012)  
Strengths and Difficulties Questionnaire 
SDQ-P Difficulties Score  f,g 6.7 (4.7) 6.5 (4.9) 0.202 (-0.136 0.540)  0.119 (-0.271, 0.509)  
SDQ-T Difficulties Score  f,h 4.0 (4.4) 3.7 (4.5) 0.347 (-0.080, 0.774)  0.252 (-0.235, 0.740)  
SDQ-P Prosocial Behaviour Score g 8.5 (1.7) 8.5 (1.7) -0.027 (-0.146, 0.092)  -0.015 (-0.147, 0.118) 
SDQ-T Prosocial Behaviour Score h 8.0 (2.3) 8.2 (2.3) -0.252 (-0.472, -0.032)  -0.184 (-0.426, 0.058)  
aInverse probability of treatment weights (IPTW) were estimated using a propensity score model containing the following covariates: 
maternal age, maternal ethnicity, maternal NZ deprivation decile score, parity, BMI prior to prescription initiation, smoking status, 
timing of GDM diagnosis and treatment, history of GDM and history of GDM treatment. The IPTW adjusted model uses imputed 
values for parity, BMI, and smoking status. These models are also adjusted for geographic region. 
bWeight was avaliable for 3,156 children (80.4%). Weight measurements were missing for 21.5% of insulin-exposed children and 
17.9% of metformin exposed children. 
cZ-scores and percentiles were calculated based on a WHO 2006 reference standard. 
dHeight was available for 3,154 children (80.3%).  Height measurements were missing for 21.5% of insulin-exposed children and 
17.9% of metformin exposed children. 
eWeight for length and BMI measurements were calculated for children with non-missing weight and height (N=3,154, 80.3%). Height 
was rounded to the nearest 0.5 for determining weight-for-length percentiles. 
fSDQ Difficulties Scores were calculated by summing scores from four scales: emotional problems, conduct problems, 
hyperactivity/inattention, and peer relationship problems.  
gSDQ-P values were available for 3,129 children (79.7%). Scores could not be calculated for 22.3% of children exposed to insulin, 
and 18.4% of children exposed to metformin. 
gSDQ-T values were available for 1,681children (42.8%). Scores could not be calculated for 47.1% of children exposed to insulin, and 






Table 5.3 Unadjusted and adjusted risk ratio estimates comparing child health outcomes between children exposed in utero to 






Unadjusted Risk Ratio 
(95% CI) 
Adjusteda Risk Ratio 
(95% CI)  
N (%) N (%)   
Child Growth Outcomes     
Weight ≥ 85th Percentile 600 (36.6) 520 (34.3) 1.07 (0.98, 1.18) 1.04 (0.93, 1.16) 
Weight ≥ 97th Percentile 235 (14.4) 202 (13.3) 1.08 (0.90, 1.28) 0.93 (0.76, 1.13) 
Weight z score ≥1 SD 616 (37.6) 549 (36.2) 1.04 (0.95, 1.14) 1.01 (0.91, 1.12) 
Weight z score ≥2 SD 207(12.6) 172 (11.4) 1.13 (0.94, 1.37) 0.94 (0.76, 1.18) 
     
Height ≥ 85th Percentile 441 (26.9) 341 (22.5) 1.19 (1.05, 1.34) 1.06 (0.92, 1.22) 
Height ≥ 97th Percentile 136 (8.3) 95 (6.3) 1.32 (1.03, 1.70) 1.08 (0.81, 1.43) 
Height z score ≥1 SD 450 (27.5) 355 (23.4) 1.17 (1.03, 1.31) 1.05 (0.91, 1.20) 
Height z score ≥2 SD 116 (7.1) 76 (5.0) 1.41 (1.07, 1.87) 1.13 (0.82, 1.54) 
     
Weight-for-Length ≥85th Percentile 600 (36.6) 612 (40.4) 0.91 (0.83, 0.99) 0.92 (0.83, 1.02) 
Weight-for-Length ≥ 97th Percentile 252 (15.4) 244 (16.1) 0.96 (0.82, 1.13) 0.91 (0.75, 1.09) 
Weight-for-Length z score ≥1 SD 599 (36.8) 614 (40.6) 0.91 (0.83, 0.99) 0.91 (0.83, 1.01) 
Weight-for-Length z score ≥2 SD 219 (13.4) 210 (13.9) 0.97 (0.82, 1.16) 0.89 (0.73, 1.09) 
     
BMI ≥ 85th Percentile 605 (36.9) 618 (40.8) 0.91 (0.83, 0.99) 0.92 (0.83, 1.01) 
BMI ≥ 97th Percentile 267 (16.3) 256 (16.9) 1.01 (0.86, 1.18) 0.92 (0.77, 1.11) 
BMI z score ≥1 SD 622 (38.0) 641 (42.3) 0.90 (0.83, 0.98) 0.91 (0.83, 1.00) 
BMI z score ≥2 SD 233 (14.2) 220 (14.5) 0.99 (0.83, 1.17) 0.89 (0.73, 1.08) 
BMI ≥ 21 59 (3.6) 51 (3.4) 1.07 (0.74, 1.55) 0.81 (0.53, 1.22) 
Strengths and Difficulties Questionnaire 
Abnormal SDQ-P Difficulties Score (≥14)f 152 (9.3) 137 (9.1) 1.03 (0.83, 1.28) 1.13 (0.88, 1.46) 
Abnormal SDQ-T Difficulties Score (≥11)g 73 (9.5) 74 (8.1) 1.16 (0.85, 1.58) 1.21 (0.85, 1.71) 
aInverse probability of treatment weights (IPTW) were estimated using a propensity score model containing the following covariates: 
maternal age, maternal ethnicity, maternal NZ deprivation decile score, parity, BMI prior to prescription initiation, smoking status, 
timing of GDM diagnosis and treatment, history of GDM and history of GDM treatment. The IPTW adjusted model uses imputed 
values for parity, BMI, and smoking status. These models are also adjusted for geographic region. 
bWeight was avaliable for 3,156 children (80.4%). Weight measurements were missing for 21.5% of insulin-exposed children and 
17.9% of metformin exposed children. 
cZ-scores and percentiles were calculated based on a WHO 2006 reference standard for children aged 0-5. One child was measured 





dHeight was available for 3,154 children (80.3%).  Height measurements were missing for 21.5% of insulin-exposed children and 
17.9% of metformin exposed children. 
e Weight for length and BMI measurements were calculated for children with non-missing weight and height (N=3,154, 80.3%). Height 
was rounded to the nearest 0.5 for determining weight-for-length percentiles. 
fSDQ-P Difficulties Scores were calculated by summing scores from four scales: emotional problems, conduct problems, 
hyperactivity/inattention, and peer relationship problems. SDQ-P values were available for 3,129 children (79.7%).  The SDQ-P 
Difficulties Score could not be calculated for 22.3% of children exposed to insulin, and 18.4% of children exposed to metformin. 
gSDQ-T Difficulties Scores were calculated by summing scores from four scales: emotional problems, conduct problems, 
hyperactivity/inattention, and peer relationship problems. SDQ-T values were available for 1,681children (42.8%). The SDQ-T 






Table 5.4 Sex-specific adjusted risk ratio estimates comparing child growth and development outcomes between children born to 
women treated with metformin versus insulin for gestational diabetes  
 












N(%) N(%) Adjusteda Risk 
Ratio (95% CI) 
N(%) N(%) Adjusteda Risk 
Ratio (95% CI) 
p-value for 
interaction 
Child Growth Outcomes  
Weight ≥ 85th Percentileb,c 354 (39.8) 311 (38.2) 1.01 (0.88, 1.16) 246 (32.9) 209 (29.8) 1.05 (0.89, 1.25) 0.6736 
Weight ≥ 97th Percentile 149 (16.7) 120 (14.7) 0.94 (0.72, 1.22) 86 (11.5) 82 (11.7) 0.88 (0.64, 1.21) 0.4213 
Weight z score ≥1 SD 361 (40.6) 329 (40.4) 0.98 (0.86, 1.11) 255 (34.1) 220 (31.4) 1.03 (0.87, 1.22) 0.5084 
Weight z score ≥2 SD 132 (14.8) 107 (13.1) 0.90 (0.68, 1.19) 75 (10.0) 65 (9.3) 0.98 (0.69, 1.39) 0.8699        
 
Height ≥ 85th Percentilec,d 257 (28.9) 203 (24.9) 1.00 (0.84, 1.21) 184 (24.6) 138 (19.7) 1.12 (0.89, 1.39) 0.6115 
Height ≥ 97th Percentile 84 (9.4) 57 (7.0) 1.05 (0.72, 1.52) 52 (7.0) 38 (5.4) 1.12 (0.72, 1.76) 0.6090 
Height z score ≥1 SD 260 (29.3) 211 (25.9) 0.98 (0.82, 1.17) 190 (25.4) 144 (20.5) 1.12 (0.90, 1.38) 0.4728 




339 (38.1) 345 (42.4) 0.91 (0.79, 1.03) 261 (34.9) 267 (38.0) 0.92 (0.78, 1.07) 0.7004 
Weight-for-Length ≥ 97th 
Percentile 
149 (16.7) 146 (17.9) 0.83 (0.65, 1.05) 103 (13.8) 98 (14.) 1.01 (0.75, 1.35) 0.6511 
Weight-for-Length z score 
≥1 SD 
338 (38.2) 347 (42.7) 0.89 (0.78, 1.01) 261 (35.1) 267 (38.1) 0.92 (0.79, 1.08) 0.6189 
Weight-for-Length z score 
≥2 SD 
128 (14.4) 129 (15.9) 0.77 (0.59, 1.00) 91 (12.2) 81 (11.5) 1.08 (0.78, 1.49) 0.3653 
       
 
BMI ≥ 85th Percentilec,e 344 (38.7) 352 (43.2) 0.89 (0.79, 1.02) 261 (34.9) 266 (38.0) 0.92 (0.79, 1.08) 0.5900 
BMI ≥ 97th Percentile 164 (18.4) 162 (19.9) 0.85 (0.67, 1.06) 103 (13.8) 94 (13.4) 1.02 (0.76, 1.38) 0.6126 
BMI z score ≥1 SD 356 (40.0) 367 (45.1) 0.89 (0.79, 1.01) 266 (35.6) 274 (39.1) 0.91 (0.78, 1.07) 0.6145 
BMI z score ≥2 SD 141 (15.8) 142 (17.4) 0.78 (0.61, 0.99) 92 (12.3) 78 (11.1) 1.08 (0.78, 1.50) 0.3507 
BMI ≥ 21 33 (3.7) 26 (3.2) 0.81 (0.44, 1.46) 26 (3.5) 25 (3.6) 0.73 (0.40, 1.34) 0.5772 
Strengths and Difficulties Questionnaire  
Abnormal SDQ-P 
Difficulties Score (≥14)f,g 


















N(%) N(%) Adjusteda Risk 
Ratio (95% CI) 
N(%) N(%) Adjusteda Risk 




Difficulties Score (≥11)f,h 
53 (5.9) 51 (6.2) 1.24 (0.82, 1.88) 20 (5.6) 23 (5.3) 1.24 (0.68, 2.25) 0.9692 
aInverse probability of treatment weights (IPTW) were estimated using sex-specific propensity score models containing the following covariates: 
maternal age, maternal ethnicity, maternal NZ deprivation decile score, parity, BMI prior to prescription initiation, smoking status, timing of GDM 
diagnosis and treatment, history of GDM and history of GDM treatment. The IPTW adjusted model uses imputed values for parity, BMI, and 
smoking status. These models are also adjusted for geographic region. 
bWeight was avaliable for 3,156 children (80.4%). Weight measurements were missing for 21.5% of insulin-exposed children and 17.9% of 
metformin exposed children. Weight was missing for 421 boys (24.7%) and 351 girls (24.2%). 
cZ-scores and percentiles were calculated based on a WHO 2006 reference standard. 
dHeight was available for 3,154 children (80.3%).  Height measurements were missing for 21.5% of insulin-exposed children and 17.9% of 
metformin exposed children. Height was missing for 422 boys (24.7%) and 352 girls (24.2%). 
e Weight for length and BMI measurements were calculated for children with non-missing weight and height (N=3,154, 80.3%). Height was 
rounded to the nearest 0.5 for determining weight-for-length percentiles. 
fSDQ Difficulties Scores were calculated by summing scores from four scales: emotional problems, conduct problems, hyperactivity/inattention, 
and peer relationship problems.  
gSDQ-P values were available for 3,129 children (79.7%) (1,692 boys, 1,437 girls).  The SDQ-P Difficulties Score could not be calculated for 
22.3% of children exposed to insulin, and 18.4% of children exposed to metformin. 
hSDQ-T values were available for 1,681children (42.8%) (888 boys, 793 girls). The SDQ-T Difficulties Score could not be calculated for 47.1% 
of children exposed to insulin, and 38.7% of children exposed to metformin. 
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CHAPTER 6 – DISCUSSION 
Globally, the prevalence of GDM is rising as maternal obesity and insulin resistance 
becomes more widespread. Women diagnosed with GDM are at greater risk of adverse 
pregnancy outcomes, including high blood pressure and high birthweight babies. This 
contributes to an increased need for birth interventions like labor induction and c-section 
delivery. Infants born to women with GDM are also at increased risk of low blood glucose at 
birth (neonatal hypoglycemia) and birth injuries (e.g., shoulder dystocia). These 
complications can be severe, particularly in resource-poor settings without access to 
advanced medical technology.  
Managing GDM has been shown to be effective for mitigating these adverse 
outcomes, and therefore critical to improving maternal and infant health outcomes. 
Randomized controlled trials have shown that active management of GDM with diet or 
pharmacologic therapy reduces the risk of adverse maternal and neonatal outcomes 
compared with usual prenatal care without treatment.  Identifying treatment strategies that 
can be implemented and accepted in multiple resource settings is therefore essential to 
addressing the adverse health outcomes of unmanaged GDM. Women may find insulin 
prohibitively expensive or challenging to obtain and store, and these barriers may be 
amplified in resource-poor areas. In a recent focus group study, 16 US women requiring 
pharmacologic management of GDM were asked about their experiences with diagnosis 
and treatment, including the options they considered and their concerns related to these 
options (120). Although some women reported feelings of relief after starting insulin, most 
struggled to manage their blood sugar and even reported episodes of hypoglycemia. Many 
women participating in the focus groups reported that taking insulin
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was inconvenient, cumbersome, and physically and emotionally uncomfortable. While 
women were interested in alternate treatment options like oral hypoglycemic agents (OHAs), 
these were not offered, and questions remained about how these medications work and 
impact their child’s health in the future. Providing high-quality evidence for the safety and 
effectiveness of these treatment options is therefore incredibly valuable for guiding women 
through treatments that work to manage their condition and fit their lifestyles.  
Prenatal care providers have been increasingly interested in using OHAs as first-line 
treatment for GDM. Results from randomized controlled trials suggest that OHAs glyburide 
and metformin are both options that would be as effective as insulin in maintaining glycemic 
control for women diagnosed with GDM. However, these studies were not powered to 
evaluate modest but clinically meaningful differences in adverse maternal and neonatal 
outcomes. Such differences may only become evident in studies with large sample sizes or 
meta-analyses. In the case of glyburide, results from a large observational study and recent 
meta-analyses led the ACOG to change its recommendation on using glyburide as a first-
line treatment in the US (63), while metformin remains an option for women who cannot 
safely administer insulin. Estimates from meta-analyses suggest that metformin may actually 
be more effective than insulin in preventing short-term complications, but even these 
estimates were limited in precision due to small sample sizes from randomized trials. To 
address the uncertainty regarding the comparative safety and effectiveness of metformin 
versus insulin, we conducted a large, population-based cohort of New Zealand pregnancies 
treated pharmacologically for GDM.  
6.1 Summary of Findings 
We did not observe increased risks of adverse maternal or neonatal outcomes 
associated with metformin use compared with insulin. Compared to insulin, metformin use 
was associated with reduced risks of elective c-section, labor induction, infant macrosomia, 
neonatal hypoglycemia, and preterm birth. Our estimates for rare adverse outcomes such as 
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preeclampsia and shoulder dystocia do not suggest major differences in risk of these events 
among metformin and insulin users. While rare, our confidence intervals for these 
associations were more precise than even the combined estimates from a recent meta-
analysis.10 In stratified models, we observed variation in elective c-section estimates by 
ethnicity, as well as variation in the degree to which metformin use affected neonatal 
hypoglycemia risk. We also observed variation by infant sex in the risk difference estimates 
for the association of metformin versus insulin treatment and two outcomes, neonatal 
hypoglycemia and large-for-gestational-age. This suggests that while metformin may overall 
be an appropriate alternative to insulin for first-time GDM treatment, there may be 
individuals for whom insulin is more effective. 
We were also able to leverage results from a universal pre-school assessment 
provided as part of regular well-child care to children in New Zealand to study health 
outcomes in children born to mothers who had been treated with metformin or insulin for 
GDM. In this study, we did not observe meaningful differences in child growth or 
developmental outcomes at age 4. Children whose mothers were treated initially with 
metformin versus insulin to manage GDM were similar with respect to weight, height, and 
BMI and we did not observe statistically or clinically significant differences between them 
after adjusting for measured covariates. We observed variation in model estimates by child 
sex, but there was not a statistically significant interaction between treatment and sex. Our 
findings are consistent with prior studies focused on child health outcomes at younger ages. 
6.2 Strengths and Limitations 
Our cohort study was conducted using population-level healthcare data and 
represents GDM treatment and outcomes throughout New Zealand. By using a maternity 
care dataset linked with other clinical and demographic data, we were able to incorporate 
information not usually found in administrative databases for pregnancy research, including 
information on gestational age and birthweight. Our study focused on maternal and infant 
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outcomes was approximately ten times the size of the largest randomized controlled trial to 
date. This allowed us to calculate estimates of association with greater precision, and to 
study outcomes that previously studies did not have the power to examine. Additionally, we 
were able to investigate associations within key subgroups, including estimating ethnicity- 
and infant sex-specific measures of association.  
We did not have access to women’s laboratory values from either outpatient or 
home-based glucose testing. This means that we could not control for baseline disease 
severity as measured by blood glucose levels. However, other indicators of disease severity 
like maternal BMI and timing of diagnosis and treatment were similar between the two 
groups. Additionally, we were also unable to restrict our cohort to women who were 
diagnosed with GDM based on results from oral glucose tolerance tests. Instead, we 
learned from discussions with NZ clinicians that women diagnosed with GDM are provided 
free blood glucose monitors and prescriptions for glucose test strips to identify newly 
diagnosed patients in prescription claims. While we were able to exclude women who had 
filled a prescription for blood glucose test strips or antidiabetics prior to 24 weeks gestation, 
it is possible that some women may have had undetected type 2 diabetes prior to pregnancy 
or GDM screening.   
Our study had missing data on BMI, smoking status, parity and ethnicity for some 
women. We employed an advanced epidemiologic method for addressing missing data, 
multiple imputation using chained equations, for women with missing covariate information. 
However, because BMI is only reported at the first prenatal care encounter in the Maternity 
Collection, we did not have information on maternal weight gain during pregnancy, which is 
a likely confounder. We were also missing some granularity for certain outcomes. We used 
ICD-10 codes to define neonatal hypoglycemia and could not confirm this diagnosis based 
on laboratory values or determine severity. Our estimates are consistent with previous 
studies, including a recent meta-analysis, suggesting that an ICD-10 code-based definition 
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may be a suitable proxy. Likewise, we were unable to determine how many hours an infant 
stayed in the neonatal intensive care unit, and therefore could not distinguish between short- 
and long-term stays. However, we were able to observe if the infant remained in the hospital 
after the mother had already been discharged, indicating potentially serious complications 
that required extra medical attention. 
Since this study was conducted in New Zealand, its results and conclusions may not 
be generalizeable to other populations. GDM disproportionately affects Black and Hispanic 
women in the US, but these ethnic groups are not well-represented in New Zealand. If there 
are ethnic differences in the effectiveness of metformin compared with insulin, our results 
may not be reproducible in a US population. Additionally, the New Zealand healthcare 
system is publicly-funded, and cost may be a less significant barrier to diagnosis and 
treatment of GDM than it is in the US. Women diagnosed with GDM in the US may be more 
likely to have undetected or untreated type 2 diabetes than in New Zealand and may also 
have a difficult time affording insulin treatment. Future research should examine how cost 
and healthcare history factor in to GDM treatment decisions. Because insulin may be a more 
expensive treatment in certain settings, including the US, metformin may be the most 
feasible option for women with GDM. 
6.3 Public Health Implications 
There is substantial uncertainty surrounding the options for pharmacologic treatment 
of GDM. Based on the results of our study, initiating metformin as pharmacologic therapy 
appears to be at least as effective as insulin for reducing serious adverse events at birth. In 
some cases metformin may be a better first line option for treating GDM than insulin, which 
is consistent with results from a recent meta-analysis (52). We observed a reduced risk of 
large-for-gestational-age, neonatal hypoglycemia, and NICU admissions associated with 
metformin versus insulin initiation. However, approximately 12% of women initiation 
metformin required supplemental treatment with insulin. This study provides new evidence 
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to support the consideration of metformin as a first-line pharmacotherapy for GDM. Careful 
blood glucose monitoring will be necessary to determine if supplemental treatment with 
insulin is indicated. 
In our analyses stratified by ethnicity, we did not see substantial variation in the 
effectiveness of metformin compared with insulin for most outcomes. However, metformin 
was associated with a meaningfully reduced risk of neonatal hypoglycemia compared with 
insulin for every ethnicity except Asian women, for whom there was no difference in risk. We 
observed similarly attenuated estimates for Asian women when comparing risks of large-for-
gestational-age as well. This may suggest that there are subgroups in whom metformin is 
clearly a better option for preventing serious adverse neonatal outcomes compared with 
insulin.   
One major reason that metformin has not been universally endorsed as a first-line 
treatment for GDM is the concern that it may adversely impact fetal development in ways 
that insulin would not. Metformin has been shown to cross the placenta due to its small 
molecular size, while insulin does not. Additionally, metformin and insulin may differ in how 
effective each medication is for managing GDM and avoiding adverse infant outcomes like 
macrosomia or neonatal hypoglycemia. This can have important downstream consequences 
for child health. Without long-term health data in children born to women treated with 
metformin for GDM, patients and providers have not felt confident in metformin’s safety for 
use during pregnancy. Our investigation of the comparative effectiveness and safety of 
metformin versus insulin therefore provides desired information to help guide treatment 
decisions for women requiring pharmacologic therapy to treat GDM.  
6.4 Conclusions 
 This study presents new evidence for the comparative effectiveness and safety of 
initial metformin pharmacotherapy for GDM compared with insulin. Our examination of long-
term growth and development outcomes in preschool-aged children is a novel contribution 
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to the literature and can be considered by physicians and patients when making treatment 
decisions for GDM. Future research should focus on indicators of treatment failure in women 
initiating metformin to refine pharmacotherapy recommendations. Additionally, more 
research is needed to examine the effectiveness of metformin compared to insulin in 
subgroups with elevated risk for GDM that this study could not include, specifically Black 











Study Population Results Limitations 
Maternal and Infant Outcomes 







Total N=63   
-Women receiving 
prenatal care at the 
University of 
Mississippi Medical 
Center in Jackson, MS 
-Diagnosis of GDM  
with 2 or more 
abnormal values during 
3-h glucose tolerance 
test (cut-off s1-h 190 
mg/dL, 2-h 165 mg/dL, 
3-h 145 mg/dL) 
More caesarean deliveries 
occurred in insulin group (n=10) 
versus metformin group (7). 
Mean birthweight between 
treatment groups was similar 
(insulin: 3500.2 ± 700.5, 
metformin: 3451.8 ± 727.5). 
There were no cases of neonatal 
hypoglycemia in the metformin 
group, and 2 cases for the insulin 
group. 
-Small sample size (<100) 
-Treatment groups not 
well-balanced by pre-
pregnancy weight, 
gravidity, or ethnicity. 
Metformin group patients 
had higher BMI than 
insulin patients.  









-Women aged 18 to 45 
years 
between 20-33 weeks 
gestation 
-10 New Zealand and 
Australia urban 
hospitals  
-Diagnosis of GDM 
according to 
Australasian Diabetes 
in Pregnancy Society  
-Had more than one 
fasting glucose 
measurement above 
5.4 mmol/L or more 
than one 2-hour 
measurement above 
6.7 mmol/L. 
Primary neonatal composite 
outcome: RR=0.99 (95% CI 0.80-
1.23) 
Neonatal hypoglycemia: RR 0.81 
(95% CI 0.59-1.12) 
Respiratory distress: RR 0.76 
(95% CI 0.37-1.59) 
Birth trauma: RR 0.96 (95% CI 
0.49-1.87) 
Preterm birth (all): RR 1.60 (95% 
CI 1.02-2.52) 
Apgar score <7: RR 3.06 (95% CI 
0.32-29.26) 
NICU admission: RR 0.89 (95% 
CI 0.66-1.19) 
-Women receiving 
metformin were more 
likely to have ≥3 prior 
pregnancy terminations or 
miscarriages and less 
likely to be of Indian or 
Polynesian ethnicity.  
-Treatment was open-label 
and not blinded.  
-Primary composite 
outcome comprises events 
of varying clinical 
significance. The sample 
size is large for an RCT 
but too small overall to 
detect small but 
meaningful differences in 










Study Population Results Limitations 





Total N=97 (100 
enrolled) 
-Women with singleton 
pregnancies between 
12-34 weeks gestation 
(mean age 32) 
-Attending maternity 
welfare clinics at two 
hospitals in Kajaani, 
Finland 
-Diagnosed with GDM 
based on risk factor-
based screening with 
2-hour OGTT 
LGA: RR 0.90 (95% CI 0.24-2.98) 
Neonatal hypoglycemia: RR 0.70 
(95% CI 0.23-1.89) 
Hyperbilirubinemia: RR 0.80 
(95% CI 0.43-1.39) 
NICU admission: RR 0.70 (95% 
0.29-1.60) 
Caesarean section: RR 1.90 
(95% 0.99-3.31) 
Labor induction: RR 1.00 (95% CI 
0.67-1.45) 
-Small sample size (<100) 
-Blinding was not possible 
for women due to route of 
administration, but unclear 
if providers were blinded 
to treatment as well. 
Niromanesh et 








-Women with singleton 
pregnancies aged 18 to 
40 years 
-Between 20 and 34 
weeks gestation 
-Receiving prenatal 
care at one of three 
hospitals in Tehran, 
Iran 
-Diagnosed with GDM 
using Carpenter and 
Coustan guidelines 
Birthweight >90th percentile: RR 
0.5 (95% CI 0.3-0.9) 
Neonatal hypoglycemia: RR 1.5 
(95% CI 0.3-8.7) 
Respiratory distress: RR 2.5 
(95% CI 0.5-12.5) 
Hyperbilirubinemia: RR 2.0 (95% 
CI 0.8-4.7) 
Preterm birth (all): RR 2.2 (95% 
CI 0.7-7.0) 
NICU admission: RR 2.5 (95% CI 
0.5-12.5) 
Caesarean section (all): RR 0.7 
(95% CI 0.2-2.2) 
Caesarean section (emergency): 
RR 1.6 (95% CI 0.9-2.7) 
Shoulder dystocia: RR 0.5 (95% 
CI 0.1-2.6) 
Preeclampsia: RR 0.7 (95% CI 
0.2-2.2) 
-Small sample size (<200) 
-2-hour OGTT values 
slightly higher for insulin 
group.  
-Participants were not 
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population as Rowan et 
al. 2008 (MiG trial) 
-Subset of women with 
available cord plasma 
samples. 
Metabolic markers were similar 
between neonates exposed to 
metformin and insulin. Glucose in 
cord plasma was similar (4.38 
mmol/l [95% CI 4.15-4.63] for 
metformin-exposed; 4.46 mmol/l 
[95% CI 4.28-4.65] for insulin-
exposed).  
Higher maternal values of HbA1c 
and triglycerides were associated 
with birthweight >90th percentile 
in both treatment groups.  
Glucose values from 36 weeks 
gestation to 6-8 weeks 
postpartum increased more for 
women treated with insulin (mean 
4.29 to 5.04) than metformin 
(mean 4.43 to 4.94).  
-Sample size varied based 
on availability of samples. 
-There is little information 
on the baseline 
characteristics of the 
subset of mothers with 
available measurements, 
and comparisons between 
metformin and insulin 
treated groups do not 
appear to control for these 
differences. 








-Women seen at a 
hospital in Islamabad, 
Pakistan beyond 14 
weeks gestation 
-Diagnosed with 
diabetes by fasting 
blood sugar and 
random blood sugar 
tests 
There were no statistically 
significant differences (p<0.05) 
between the two groups with 
regard to post-treatment blood 
sugar levels and HBA1C results. 
-Small sample size (<100) 
-Sample size included 
both overt diabetes and 
GDM cases. 
Mesdaghinia et 







-Women with singleton 
pregnancies aged 18 to 
45 years 
-Between 24 and 34 
weeks gestation 
-Receiving care at one 
hospital in Isfahan, Iran 
-Diagnosed with GDM 
with two-step criteria 
Results of chi-squared test 
showed no significant differences 
(p<0.05) with regard to birth 
weight, LGA, hypoglycemia, birth 
defects, shoulder dystocia, 
stillbirth, sepsis, or Apgar scores. 
Significant differences were found 
for jaundice, respiratory distress, 
-Small sample size (200). 
-Participants weren't 
blinded but providers 
were. 
-Very little information 
about outcome definitions 
(i.e., spontaneous versus 
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(glucose challenge test 
followed by glucose 
tolerance test) 













-Women with singleton 
pregnancies aged 18 to 
45 years 
-Between 24 and 33 
weeks of gestation 
-Diagnosed with GDM 
according to the 
Australasian Diabetes 
in Pregnancy Society 
guidelines 
There were no statistically 
significant differences (p<0.05) 
between the two groups with 
regard to hyperbilirubinemia, 
respiratory distress syndrome, 
NICU admissions, shoulder 
dystocia, hypoglycemia, Apgar 
scores, macrosomia, small for 
gestational age, and stillbirth. The 
average birth weight and 
postnatal blood sugar were 
higher for the metformin treated 
women but not significantly. 
-Small sample size (<200) 
-Study says participants 
were double-blinded but 
unclear how they were 
blinded to receiving 
metformin (pill) versus 
insulin (injection) 








-Women with singleton 
pregnancies with GDM 
delivering after 20 
weeks of gestation 
-Seen at National 
Women's Health in 
Auckland, NZ 
-Diagnosed with GDM 
based on fasting 
glucose of 5.5 mmol/L 
or higher or 2-h 
glucose of 9.0 mmol/L 
or higher 
Women receiving metformin were 
less likely to have LGA infants, 
preterm birth (iatrogenic), NICU 
admissions, and use of 
intravenous glucose to the infant.  
-Small sample size 
(<1,000 for medication 
users) 
-No information on 
treatment duration, 
glucose control achieved 
after treatment. 
-Women receiving insulin 
were more likely to be 
European; women 
receiving metformin more 
likely to be Maori or 
defined as Other Asian.   
-Effect estimates were not 
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-Women with singleton 
pregnancies diagnosed 
with GDM from risk 
factor-based screening 
-Treated at one 
hospital in Finland 
Macrosomia: OR 0.6 (95% CI 
0.2-1.9) 
Hypoglycemia: OR 0.4 (95% CI 
0.2-0.9) 
Hyperbilirubinemia: OR 1.1 (95% 
CI 0.4-2.9) 
Respiratory distress: NS 0.0 (too 
small) 
Caesarean section delivery: OR 
1.6 (95% CI 0.6-4.2) 
-Insulin users had higher 
OGTT values. They were 
more likely to have labor 
induced and were more 
likely to be primipara.  
-Patients were matched on 
pre-pregnancy BMI 
(categories) and age 
(categories) but analyses 
did not control for other 
confounders. 














GDM (diagnosed as 2-
h glucose value ≥ 
7.8mmol/l at 28 
weeks). Inadequate 
control defined as three 
or more tests out of 
range (<6.0 mmol/l 
fasting, <8.0 mmol/l 1-
h, <7.0 mmol/l 2-h) 
within 2 weeks or 
within 1 week of any 
treatment change 
-Seen at antenatal 
clinic in Surrey, UK 
hospital between 
January 2007 and July 
2008 
Women receiving metformin were 
significantly less likely to have 
preeclampsia (2 vs 9%); preterm 
birth (0 vs 10%); or admission to 
the NICU (6 vs 19%) than those 
receiving insulin. Infants exposed 
to metformin were less likely to 
be LGA >90th percentile (14 vs 
25%) and had smaller birthweight 
overall (3372 ± 474 vs 3511 ± 
511); less likely to have jaundice 
(8 vs 30%), hypoglycemia (9 vs 
18%), and NICU admission (6 vs 
19%).  
-Small sample size (200 
total). 
-Women in insulin group 
more likely to have prior 
gestational diabetes (25%) 
than metformin (13%), and 
had higher OGTT values 
overall.  
-Gestational age at entry 
(defined as inadequate 
glucose control) was 
earlier for insulin group (30 
weeks) than metformin (32 
weeks).  
-Proportions and mean 
values were compared 
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Child Health Outcomes 









(731 from MiG 
trial) 
-2-year old children 
born to women 
participating in the MiG 
trial (see Rowan et al. 
2008 above for details 
on enrolled mothers) 
Children exposed to metformin 
and insulin in the MiG trial had 
similar anthropometric 
measurements. Children exposed 
to metformin had larger chest 
circumference (52.1 ± 3.0 vs 51.6 
± 3.0), upper-arm circumference 
(17.2 ± 1.5 vs 16.7 ± 1.5), 
subscapular skinfold thickness 
(6.3 ± 1.9 vs 6.0 ± 1.7) and 
biceps skinfold thickness (6.0 ± 
1.9 vs 5.6 ± 1.7) in centimeters as 
compared with insulin-exposed 
children. 
In children with available DEXA 
measurements (57 per group), 
children exposed to metformin 
had a smaller % of abdominal fat 
mass (5.3 ± 1.3 vs 5.6 ± 1.3) than 
insulin-exposed children but not 
significantly.  
-Small sample size (318 
overall, 114 with DEXA 
measurements) 
-Mothers of children 
participating in this follow-
up study who had received 
metformin were more 
likely to be 
European/Caucasian (57.1 
vs 47.6%) than those who 
had received insulin and 
were more likely to have 
smoked during pregnancy 
(10.4 vs 6.1) though not 
statistically significantly. 
-Statistical significance 
partly driven by comparing 
continuous outcomes; 
differences may not be 
meaningful. 







Total N=93 (100 
from original 
trial) 
-18-month old children 
born to women 
participating in a 
previous trial (see Ijas 
et al 2010 above for 
details on enrolled 
mothers) 
At 12 and 18 months, children 
exposed to metformin were more 
likely to have height ≥95% 
percentile (15.6 vs 2.1% at 12 
months, 13.3 vs 4.2% at 18 
months) than insulin-exposed 
children. At all three time points, 
metformin-exposed children 
-Small sample size (<100) 
-Mothers of children 
randomized to metformin 
were less likely to be 
smokers (2.2 vs 8.3%) 
than insulin-assigned 
mothers.  
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weighed more than insulin-
exposed children. Metformin-
exposed infants had higher 
birthweight overall at the time of 
delivery. Metformin- and insulin-
exposed were similar with respect 
to development.  
maternal pre-pregnancy 
BMI was a strong predictor 
of child weight at 18 
months but do not control 
for this or other 
confounders in their 
primary analysis. 










-2-year old children 
born to women 
participating in a 
previous trial (see 
Terrti et al. 2008 above 
for details on enrolled 
mothers) 
Children had lower scores on the 
Bayley-III language scale than 
the normative Finnish sample. 
Differences in scoring between 
metformin- and insulin-exposed 
infants were small and 
inconsistent.  
-Small sample size (<200) 
-Metformin-treated 
mothers were less likely to 
be smokers (5.5 vs 
12.9%). 
Information on the 






APPENDIX 2. CONCEPTUAL DIAGRAM DEPICTING PROPOSED RELATIONSHIPS BETWEEN STUDY EXPOSURE, 
OUTCOMES, AND CONFOUNDERS 
 89 





APPENDIX 4. TABLE OF MATERNAL AND NEONATAL OUTCOMES, STRATIFIED BY PRIORITIZED ETHNICITY 
European 
 Event Counts, (%)  Unadjusted  IPTW-Adjusteda 
 Metformin  Insulin        
Maternal Outcome (N=1085)  (N=1468)  RR (95% CI)  RD (95% CI)  RR (95% CI) RD (95% CI) 
Elective c-section 249 (23.0) 408 (27.8)  
0.83 (0.72, 
0.95) 
 -4.8 (-8.3, -
1.4) 






193 (17.8) 255 (17.4)  
1.03 (0.86, 
1.22) 
 0.4 (-2.6, 3.5)  
1.02 (0.85, 
1.21) 
0.5 (-2.6, 3.6) 
Induction 545 (50.2) 786 (53.5)  
0.94 (0.87, 
1.01) 





Infant Outcome          
Birthweight (g) 
(Mean, SD)b b,c 
3438.0 (503.8) 3440.5 (525.1)  -1.92 (-42.59, 38.74) p=0.93  -7.92 (-50.22, 34.38) p=0.71 
Large-for-
gestational-ageb,d 
154 (14.2) 268 (18.3)  
0.78 (0.65, 
0.94) 





Macrosomiab,e 131 (12.1) 174 (11.9)  
1.02 (0.82, 
1.26) 
 0.2 (-2.4, 2.8)  
1.06 (0.85, 
1.32) 
0.1 (-2.5, 2.7) 
Neonatal 
hypoglycemiaf 
160 (14.8) 342 (23.3)  
0.64 (0.54, 
0.75) 
 -8.4 (-11.6, -
5.5) 




NICU admissiong 178 (16.4) 441 (30.0)  
0.56 (0.48, 
0.66) 
 -13.1 (-16.3, -
9.8) 





 Event Counts, (%)  Unadjusted  IPTW-Adjusteda 
 Metformin  Insulin        
Maternal Outcome (N=555)  (N=585)  RR (95% CI)  RD (95% CI)  RR (95% CI) RD (95% CI) 
Elective c-section 77 (13.9) 122 (20.9)  
0.68 (0.52, 
0.88) 
 -6.7 (-11.0, -
2.3) 






92 (16.6) 108 (18.5)  
0.90 (0.70, 
1.16) 
 -1.9 (-6.3, 2.5)  
0.91 (0.70, 
1.19) 
-1.7 (-6.2, 2.9) 
Induction 329 (59.3) 350 (59.8)  
1.00 (0.91, 
1.10) 
 -0.0 (-5.7, 5.7)  
1.01 (0.91, 
1.11) 
0.2 (-5.7, 6.1) 
Infant Outcome          
Birthweight (g) 




 -43.85 (-107.64, 19.95) p=0.18  -45.97 (-111.82, 19.87) p=0.17 
Large-for-
gestational-ageb,d 















Macrosomiab,e 79 (14.2) 111 (19.0)  
0.77 (0.59, 
1.00) 
 -4.5 (-8.8, -
0.1) 
 0.75 (0.57, 
0.98) 
-3.7 (-8.1, 0.6) 
Neonatal 
hypoglycemiaf 
88 (15.9) 147 (25.1)  
0.63 (0.50, 
0.80) 
 -9.4 (-14.0, -
4.7) 




NICU admissiong 95 (17.1) 198 (33.9)  
0.54 (0.43, 
0.67) 
 -15.2 (-20.6, -
9.9) 





 Event Counts, (%)  Unadjusted  IPTW-Adjusteda 
 Metformin  Insulin        
Maternal Outcome (N=781)  (N=393)  RR (95% CI)  RD (95% CI)  RR (95% CI) RD (95% CI) 
Elective c-section 135 (17.3) 74 (18.8)  
0.92 (0.72, 
1.18) 
 -1.5(-6.1, 3.1)  
1.15 (0.87, 
1.52) 
1.7 (-3.4, 6.7) 
Emergency c-
section 
137 (17.5) 82 (20.9)  
0.85 (0.66, 
1.08) 
 -3.2 (-8.0, 1.6)  
0.83 (0.63, 
1.08) 
-3.4 (-8.8, 1.9) 
Induction 425 (54.4) 233 (59.3)  
0.91 (0.82, 
1.01) 
 -5.2 (-11.2, 
0.7) 




Infant Outcome          
Birthweight (g) 
(Mean, SD)b,c 
3551.3 (604.6) 3581.8 (613.7)  -23.76 (-97.66, 50.15) p=0.53  -64.67 (-147.29, 17.95) p=0.13 
Large-for-
gestational-ageb,d 











Macrosomiab,e 158 (20.2) 89 (22.7)  
0.90 (0.72, 
1.13) 
 -2.4 (-7.3, 2.6)  
0.84 (0.66, 
1.08) 
-3.1 (-8.6, 2.5) 
Neonatal 
hypoglycemiaf 
110 (14.1) 99 (25.2)  
0.57 (0.44, 
0.72) 
 -11.0 (-16.0, -
6.0) 




NICU admissiong 67 (8.6) 105 (26.7)  
0.32 (0.24, 
0.43) 
 -18.0 (-22.9, -
13.2) 





 Event Counts, (%)  Unadjusted  IPTW-Adjusteda 
 Metformin  Insulin        
Maternal Outcome (N=1,279)  (N=909)  RR (95% CI)  RD (95% CI)  RR (95% CI) RD (95% CI) 
Elective c-section 220 (17.2)  183 (20.1)  
0.85 (0.71, 
1.02) 
 -3.0 (-6.3, 0.4)  
0.93 (0.77, 
1.13) 
-1.3 (-4.8, 2.2) 
Emergency c-
section 
215 (16.8)  173 (19.0)  
0.88 (0.74, 
1.06) 
 -2.2 (-5.5, 1.1)  
0.90 (0.74, 
1.09) 
-1.8 (-5.2, 1.6) 
Induction 615 (48.1)  461 (50.7)  
0.94 (0.87, 
1.03) 
 -2.9 (-7.2, 1.4)  
0.92 (0.84, 
1.00) 
-4.5 (-9.0, 0.1) 






(Mean, SD)b b,c 
3154.0 (460.7)  3145.7 (498.9)  9.38 (-31.80, 50.56) p=0.66  40.25 (-4.84, 85.34) p=0.08 
Large-for-
gestational-ageb,d 








-1.0 (-3.8, 1.8) 
Macrosomiab,e 31 (2.4)  38 (4.2)  
0.54 (0.34, 
0.87) 
 -2.0 (-3.5, -
0.4) 
 0.79 (0.46, 
1.36) 
-1.2 (-2.8, 0.4) 
Neonatal 
hypoglycemiaf 
169 (13.2)  152 (16.7)  
0.89 (0.64, 
0.96) 
 -3.6 (-6.7, -
0.5) 
 0.97 (0.79, 
1.19) 
0.2 (-2.8, 3.2) 
NICU admissiong 99 (7.7)  191 (21.0)  
0.37 (0.29, 
0.46) 
 -13.4 (-16.5, -
10.4) 




aInverse probability of treatment weights (IPTW) were estimated using a propensity score model containing the following covariates: 
maternal age, maternal ethnicity, maternal NZ deprivation decile score, parity, BMI prior to prescription initiation, smoking status, 
timing of GDM diagnosis and treatment, history of GDM and history of GDM treatment. The IPTW adjusted model uses imputed 
values for parity, BMI, and smoking status. These models are also adjusted for geographic region. 
bBirthweight values were missing for 63 infants (29 metformin, 34 insulin). 
cLinear regression was used to compare mean birthweight in infants treated initially with metformin versus insulin. 
dLarge-for-gestational-age is defined as a birthweight greater than the 90th percentile. These percentiles were calculated using a 
sample of New Zealand infants born between 2001 and 2015 with available data on birthweight and gestational age (n=850,506). 
These percentiles are additionally sex- and ethnicity-specific. 
eMacrosomia is defined as birthweight greater than 4,000g.  
fHospitalization data for infants were missing for 39 delivery events (18 metformin, 21 insulin).  







APPENDIX 5. TABLE OF MATERNAL AND NEONATAL OUTCOMES FOR DELIVERIES AFTER 2008 
 Events (%) Unadjusted IPTW-Adjusteda 
 Metformin Insulin     
Maternal Outcome (N=3,646) (N=2,717) RR (95% CI) RD (95% CI) RR (95% CI) RD (95% CI) 
Elective c-section 683 (18.7) 635 (23.4) 0.80 (0.73, 0.88) -4.6 (-6.7, -2.6) 0.89 (0.80, 0.99) -2.4 (-4.5, -0.2) 
Emergency c-section 625 (17.1) 485 (17.9) 0.96 (0.86, 1.07) -0.7 (-2.6, 1.2) 1.00 (0.89, 1.12) 0.0 (-2.0, 2.0) 
Induction 1885 (51.7) 1502 (55.3) 0.93 (0.89, 0.98) -3.7 (-6.1, -1.2) 0.91 (0.86, 0.95) -5.3 (-8.0, -2.6) 
Infant Outcome       
Birthweight (g) (Mean, 
SD)b,c 
3367.0 (535.5) 3365.4 (545.8) 3.28 (-23.73, 30.28)  20.36 (-9.15, 49.88)  
Macrosomiab,d 383 (10.5) 295 (10.9) 0.96 (0.83, 1.11) -0.4 (-2.0, 1.1) 1.02 (0.88, 1.20) 0.3 (-1.3, 2.0) 
Large-for-gestational-
ageb,e 
524 (14.4) 481 (17.7) 0.81 (0.73, 0.91) -3.3 (-5.2, -1.5) 0.86 (0.76, 0.97) -2.4 (-4.4, -0.4) 
Neonatal hypoglycemiaf 520 (14.3) 575 (21.2) 0.67 (0.60, 0.75) -7.0 (-8.9, -5.1) 0.77 (0.69, 0.86) -4.1 (-6.1, -2.1) 
NICU admissiong 429 (11.8) 803 (29.6) 0.40 (0.36, 0.45) 
-17.6 (-19.7, -
15.6) 
0.60 (0.54, 0.66) -6.9 (-8.7, -5.1) 
aInverse probability of treatment weights (IPTW) were estimated using a propensity score model containing the following covariates: maternal age, 
maternal ethnicity, maternal NZ deprivation decile score, parity, BMI prior to prescription initiation, smoking status, timing of GDM diagnosis and 
treatment, history of GDM and history of GDM treatment. The IPTW adjusted model uses imputed values for parity, BMI, and smoking status. 
These models are also adjusted for geographic region. 
bBirthweight values were missing for 54 infants (27 metformin, 27 insulin). 
cLinear regression was used to compare mean birthweight in infants treated initially with metformin versus insulin. 
dMacrosomia is defined as birthweight greater than 4,000g.  
eLarge-for-gestational-age is defined as a birthweight greater than the 90th percentile. These percentiles were calculated using a sample of New 
Zealand infants born between 2001 and 2015 with available data on birthweight and gestational age (n=850,506). These percentiles are 
additionally sex- and ethnicity-specific.  
fHospitalization data for infants were missing for 35 delivery events (17 metformin, 18 insulin).  






APPENDIX 6. TABLE OF MATERNAL AND NEONATAL OUTCOMES, STRATIFIED BY INFANT SEX 
 









 N=1785 N=1584 
 
 
N (%) N (%) Adjusted Risk 
Difference (95% 
CI)a 
 N (%) N (%) Adjusted Risk 
Difference (95% 
CI)a 
Macrosomiab,c 237 (11.8) 246 (13.4) -0.6 (-2.8, 1.6)  168 (9.4) 169 (10.7) -1.0 (-3.2, 1.2) 
Large-for-
gestational-ageb,d 
265 (13.2) 343 (18.7) -4.8 (-7.3, -2.3) 
 
284 (15.9) 310 (19.6) -2.0 (-4.8, 0.8) 
Neonatal 
hypoglycemia 
295 (14.7) 423 (23.0) -6.3 (-9.0, -3.7) 
 
248 (13.9) 331 (20.8) -3.5 (-6.1, -0.9) 
Respiratory 
distress 
114 (5.7) 147 (8.0) -1.2 (-2.9, 0.4) 
 
80 (4.5) 97 (6.1) -0.5 (-2.2, 1.1) 
NICU admissiond 244 (12.1) 521 (28.4) -6.3 (-8.6, -4.1)  214 (12.0) 441 (27.7) -5.3 (-7.5, -3.0) 
Preterm birthd 153 (7.6) 175 (9.4) -1.6 (-3.5, 0.2)  116 (6.5) 136 (8.5) -1.5 (-3.4, 0.4) 
aInverse probability of treatment weights (IPTW) were estimated using sex-specific propensity score models containing the 
following covariates: maternal age, maternal ethnicity, maternal NZ deprivation decile score, parity, BMI prior to prescription 
initiation, smoking status, timing of GDM diagnosis and treatment, history of GDM and history of GDM treatment. The IPTW 
adjusted model uses imputed values for parity, BMI, and smoking status. These models are also adjusted for geographic region. 
 bBirthweight values were missing for 63 infants (29 metformin, 34 insulin). 
cMacrosomia is defined as birthweight greater than 4,000g.  
dLarge-for-gestational-age is defined as a birthweight greater than the 90th percentile. These percentiles were calculated using a 
sample of New Zealand infants born between 2001 and 2015 with available data on birthweight and gestational age (n=850,506). 
These percentiles are additionally sex- and ethnicity-specific.  
dNICU admission is defined as a hospitalization event with a health specialty code for a Level II or Level III neonatal intensive care 
unit. 
ePreterm birth is defined as gestational age <37 weeks. 
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APPENDIX 8. COMPARISON OF PREVIOUS STUDY ESTIMATES 
 
*Indicates a risk ratio calculated from reported proportions  
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APPENDIX 10. TABLE OF SEX-STRATIFIED CHILD GROWTH AND DEVELOPMENT OUTCOMES FROM ADJUSTED LINEAR 
REGRESSION MODELS 
 



















Child Growth Outcomes 
Weight z-score   0.8 (1.3) 0.9 (1.2) -0.125(-0.272, 0.022)  0.7 (1.1) 0.6 (1.2) 0.014 (-0.122, 0.151)  
Height z-score   0.4 (1.2) 0.3 (1.0) 0.006(-0.113, 0.125)  0.3 (1.1) 0.1 (1.1) 0.080 (-0.049, 0.209)  
Weight for Length z-score   0.8 (1.4) 0.9 (1.3) -0.125(-0.272, 0.022)  0.7 (1.3) 0.8 (1.3) 0.015 (-0.122, 0.151)  
BMI z-score   0.8 (1.5) 1.0 (1.4) -0.192(-0.352, -0.032)  0.7 (1.3) 0.8 (1.3) -0.050 (-0.198, 0.098)  
Strengths and Difficulties Questionnaire 
SDQ-P Difficulties Scoref,g   7.2 (4.9) 6.9 (5.2) 0.235(-0.312, 0.783)  6.2 (4.4) 6.1 (4.4) 0.041 (-0.501, 0.583)  
SDQ-T Difficulties Score f,h  4.7 (4.9) 4.3 (4.9) 0.266(-0.475, 1.007)  3.3. (3.7) 3.0 (3.9) 0.333 (-0.216, 0.882)  
SDQ-P Prosocial 
Behaviour Scoreg  
8.3 (1.8) 8.4 (1.8) -0.062(-0.251, 0.127)  8.7 (1.5) 8.7 (1.6) 0.047 (-0.140, 0.235) 
SDQ-T Prosocial 
Behaviour Scoreh  
7.6 (2.4) 7.8 (2.5) -0.140(-0.495, 0.215)  8.5 (2.0) 8.7 (2.1)    -0.276(-0.578, 0.025)  
aInverse probability of treatment weights (IPTW) were estimated using sex-specific propensity score models containing the following 
covariates: maternal age, maternal ethnicity, maternal NZ deprivation decile score, parity, BMI prior to prescription initiation, smoking 
status, timing of GDM diagnosis and treatment, history of GDM and history of GDM treatment. The IPTW adjusted model uses 
imputed values for parity, BMI, and smoking status. These models are also adjusted for geographic region. 
bWeight was avaliable for 3,156 children (80.4%). Weight measurements were missing for 21.5% of insulin-exposed children and 
17.9% of metformin exposed children. Weight was missing for 421 boys (24.7%) and 351 girls (24.2%). 
cZ-scores and percentiles were calculated based on a WHO 2006 reference standard. 
dHeight was available for 3,154 children (80.3%).  Height measurements were missing for 21.5% of insulin-exposed children and 
17.9% of metformin exposed children. Height was missing for 422 boys (24.7%) and 352 girls (24.2%). 
e Weight for length and BMI measurements were calculated for children with non-missing weight and height (N=3,154, 80.3%). 
Height was rounded to the nearest 0.5 for determining weight-for-length percentiles. 
fSDQ Difficulties Scores were calculated by summing scores from four scales: emotional problems, conduct problems, 
hyperactivity/inattention, and peer relationship problems.  
gSDQ-P values were available for 3,129 children (79.7%) (1,692 boys, 1,437 girls).  Scores could not be calculated for 22.3% of 
children exposed to insulin, and 18.4% of children exposed to metformin. 
hSDQ-T values were available for 1,681children (42.8%) (888 boys, 793 girls). Scores could not be calculated for 47.1% of children 
exposed to insulin, and 38.7% of children exposed to metformin. 
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